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CHAPTER I 
 
THE HIGH-AFFINITY CHOLINE TRANSPORTER – A CRITICAL PROTEIN FOR 
THE MAINTENANCE OF CHOLINERGIC TONE 
 
CHT Function and Regulation 
 
The Cholinergic Synapse 
 Acetylcholine (ACh), one of the first identified neurotransmitters, was 
originally termed vagusstoff due to its actions in supporting vagal slowing of heart rate 
(HR) (Thayer, 2007), and has been the focus of intense research for decades (Nestler, 
2001).  ACh has been shown to regulate many physiologic functions both within the 
central nervous system (CNS) and in the periphery.  Within the CNS, cholinergic 
signaling mediated by ACh, regulates several diverse and complex functions including 
cognition, arousal, mood and motor circuits (Kasa, 1986; Nestler, 2001).  These CNS 
cholinergic projections, common to human and rodent brain, arise from several nuclei 
that are clustered in two areas:  the basal forebrain comprising the medial septal nucleus 
and the nucleus basalis of Meynert, projecting to the hippocampus and cerebral cortex, 
and upper brain stem cholinergic nuclei which project to the thalamus and medullary 
nuclei such as the ventral tegmental area (Figure 1). Within the basal ganglia exist large 
numbers of cholinergic interneurons which serve as critical components of the striatal 
circuitry underlying components of the pyramidal motor control system (Pisani et al., 
2007).  In the peripheral nervous system, ACh mediates functions coordinated by the  
Figure 1. Cholinergic pathways in the brain. The basal forebrain comprises the
medial septal nucleus, the nucleus basalis of Meynert, the vertical nucleus of the
diagonal band and the horizontal limb of the diagonal band (not shown). These
nuclei project to the hippocampus and cerebral cortex. Upper brain stem
cholinergic neurons include the pedunculopontine, laterodorsal tegmentum, medial
habenula and parabigeminal nuclei and project predominantly to the hippoampus
and midbrain ventral tegmentum area (VTA). Cholinergic interneurons are found
in the striatum, nucleus accumbens, olfactory tubercle, and the islands of Calleja.
BFC, basal forebrain complex; IPN, interpeduncular nucleus; LDT, laterodorsal
t t l l PPT d l ti t t l l VTA t l
 
egmen a nuc eus; , pe uncu opon ne egmen a nuc eus; , ven ra
tegmental area. Adapted from Piccioto et al. (2002) and www.CNSforum.com,
2002.
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autonomic nervous system (Figure 2A), respiration, gut motility and exocrine secretions 
(Burnstock, 1979; Lefkowitz, 1996).  Within the ANS, ACh is the predominant 
neurotransmitter at the preganglionic projections originating from within the CNS at the 
level of the medulla, for both the sympathetic (SNS) and parasympathetic nervous 
systems (PNS), mediating post-ganglionic effects via nicotinic acetylcholine receptors 
(nAChRs) (Figure 2B) (Lefkowitz, 1996).  At the post-ganglionic synapse, PNS neurons 
utilize ACh with their post-synaptic effects mediated by mAChRs, while SNS neurons 
utilize NE, with their post-synaptic effects mediated by adrenergic receptors (Lefkowitz, 
1996). 
The availability of ACh for cholinergic transmission involves a highly 
coordinated process of ACh synthesis, vesicular packaging, vesicular release, hydrolysis 
and reuptake into the presynaptic nerve terminal (Figure 3) (Bazalakova and Blakely, 
2006; Nestler, 2001).  Within the cholinergic presynaptic terminal, the enzyme choline 
acetyltransferase (ChAT) synthesizes ACh from the precursors choline and acetyl 
coenzymeA (acetyl-CoA).  Unlike the biosynthesis of catecholamines, ChAT is not 
believed to serve as the rate-limited step in the biosynthesis of ACh as the presynaptic 
concentrations of choline are much lower than the Km for ChAT (Oda, 1999).  Upon 
synthesis, ACh is packaged into synaptic vesicles by the vesicular ACh transporter 
(VAChT), and released into the synaptic cleft upon depolarization of the neuron by an 
action potential (Eiden, 2000).  Once released into the synaptic cleft, ACh interacts with 
either nAChRs or muscarinic acetylcholine receptors (mAChRs).  ACh then dissociates 
from the receptor and undergoes enzymatic inactivation by the enzyme 
acetylcholinesterase (AChE) which hydrolyzes ACh into acetate and choline 
AB
Figure 2. Autonomic Nervous System. (A) The PNS and the SNS form the
branches of the ANS. The PNS comprises the craniosacral outflow with neurons
originating in the lower brainstem and in the sacral portion of the spinal cord (S-2
to S-4). The SNS neurons originate from the lateral horns of the thoracic and
lumbar spinal cord. These neurons synapse at either paravertebral or prevertebral
columns and finally synapse at their target organ.. (B). Specific neurotransmitters
at pre- and post-ganglionic synapses of the ANS. Parasympathetic nervous
system, PNS; Sympathetic nervous system, SNS; Autonomic nervous system,
ANS; Acetylcholine, ACh, Norepinephrine, NE; Epinephrine, E. Adapted from
Pi i t t l (2002) d CNSf 2002
 
cc o o e a . an www. orum.com, .
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Figure 3. The cholinergic synapse. The enzyme choline acetyltransferase
(ChAT) synthesizes ACh in the axoplasm from the precursors choline and
acetyl coenzymeA (acetyl-CoA). ACh is then packaged into synaptic vesicles
by the vesicular ACh transporter (VAChT), and released into the synaptic
l ft l d l i ti I th ti l ft ACh i t t ithc e upon neurona epo ar za on. n e synap c c e , n erac s w
pre- and post-synaptic nicotinic (nAChR) and muscarinic (mAChR)
receptors. Presynaptic mAChRs exert an autoinhibitory effect on ACh
release, whereas presynaptic nAChR activation increases ACh release.
Synaptic ACh is hydrolyzed into acetate and choline by the enzyme
acetylcholine esterase (AChE). Choline is then transported into the
presynaptic terminal by the HC 3 sensitive high affinity choline transporter- , -
(CHT), in the rate-limiting step of subsequent ACh synthesis. Bazalakova M,
et al. (2007).
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 (Soreq and Seidman, 2001).  AChE operates at near diffusion-limited rates, thus this 
enzyme is not rate limiting in overall ACh homeostasis.  The by-product of ACh 
hydrolysis, choline, is then recycled by the presynaptic terminal in a carrier-mediated 
mechanism of high-affinity choline uptake (HACU) process, which appears to be the 
critical step in modulating the rate and extent of ACh production (Ferguson and Blakely, 
2004).  Additionally, choline can be recycled by presynaptic neurons and other cells, via 
a low affinity choline uptake (LACU) process (Ferguson and Blakely, 2004; Ribeiro et 
al., 2006).  Unlike transport proteins mediating HACU processes, low affinity choline 
uptake transporters are ubiquitously expressed in many cell types and are involved in 
choline transport for phosphatidylcholine synthesis in order to support cell membrane 
maintenance and repair (Inazu et al., 2005).  Within cholinergic nerve terminals, choline 
is required for the biosynthesis of ACh since these neurons cannot synthesize de novo, 
hence the requirement for a HACU process (Birks and Macintosh, 1961; Ferguson and 
Blakely, 2004; Macintosh et al., 1956). 
 
High Affinity Choline Uptake (HACU) and Regulation of CHT 
 High affinity choline uptake was originally described by Birks, et al. in 1961 and 
was subsequently shown to uptake choline specifically for the biosynthesis of ACh 
predominantly in presynaptic cholinergic nerve terminals (Atweh et al., 1975; Birks and 
Macintosh, 1961; Kuhar and Murrin, 1978).   In contrast to LACU, which transports 
choline in a Na+-independent manner and exhibits a lower affinity for choline (Km = 50-
100uM), HACU transports choline in a Na+-dependent manner and exhibits a higher 
affinity for choline (Km = 1-5uM) (Kuhar and Murrin, 1978; Simon et al., 1976).  HACU 
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is also inhibited by the competitive antagonist hemicholinium-3 (HC-3) (KiHACU = 10-100 
nM), versus KiLACU = 50 uM) (Simon et al., 1976; Yamamura and Snyder, 1972).   HC-3 
is a bicyclic, choline analog compound originally characterized as a respiratory paralytic 
agent (Macintosh et al., 1956).  Unlike compounds such as botulinum toxin that inhibit 
synaptic vesicle fusion machinery preventing release of ACh, and that result in lethal 
respiratory paralysis, the respiratory effects of HC-3 can be relieved by artificial 
respiration or the administration of exogenous choline demonstrating similar targets at 
the high-affinity choline transporter (Ferguson and Blakely, 2004).  The effects of 
respiratory impairment by HC-3 are consistent with cessation of ACh neurotransmission 
at the neuromuscular junction, and subsequent studies at the NMJ have shown that HC-3 
suppresses stimulation-evoked ACh release (Van der Kloot et al., 2002).  In addition to 
HC-3’s physiologic effects, the radiolabeled form of HC-3 ([3H]-HC-3) has proven a 
useful tool for identifying cholinergic terminals and studying CHT function (O'Regan, 
1988).   
 Observations that the biosynthesis of ACh was dependent upon the uptake of 
extracellular choline in Na+-dependent, HC-3 sensitive manner via a HACU process 
provided evidence that cholinergic nerve terminals possessed an alternative transporter 
(Ferguson and Blakely, 2004).  The identification of the transporter responsible for 
HACU in cholinergic neurons remained elusive due to the low density of cholinergic 
terminals in cellular preparations and the low contribution of cholinergic-neuron specific 
high-affinity choline uptake relative to low-affinity choline uptake (Diamond, 1970).  
However, though many studies demonstrated that the majority of choline uptake in 
cholinergic nerve terminals was mediated by a high-affinity, Na+-dependent, HC-3 
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sensitive mechanism, and that this process was linked to the availability of releasable 
ACh, none had identified the transporter responsible for mediating this process.   
As noted above, several studies had observed that extracellular choline was 
required to sustain ACh release and that the process of choline uptake was saturable, and 
HC-3-sensitive indicating that a separate transport process existed in cholinergic neurons.  
Additionally, ACh synthesis from exogenous radiolabeled-choline requiring Na+-
containing buffers was demonstrated in synaptosomal preparations, demonstrating that a 
distinct high-affinity, Na+-dependent choline uptake transport process existed in the CNS 
to support ACh synthesis (Yamamura and Snyder, 1972).  These results were further 
supported by experiments demonstrating a significant decrease in high-affinity choline 
uptake activity in the hippocampus following denervation of the septal-hippocampal 
pathway (Kuhar and Murrin, 1978).  Using a Xenopus laevis oocyte expression system 
combined with sequence information provided by the C. elegans Genome Project, a 
cDNA encoding the nematode and rat high-affinity choline transporter (CHT1) was 
isolated and found to demonstrate Na+-dependent, HC-3 sensitive [3H]-choline uptake 
(Okuda et al., 2000).  These observations led to the subsequent cloning of CHT in mice 
(Apparsundaram et al., 2001) and humans, as well as the chromosomal localization of 
human CHT to chromosome 2q12 (Apparsundaram et al., 2000). Recently, the 
development of choline transporter (CHT) knockout mice (CHT-/-) provided in vivo 
evidence that CHT was responsible for mediating HACU in cholinergic neurons, and 
required for the biosynthesis of ACh (Ferguson et al., 2004). 
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Localization and Expression of CHT 
Several studies have examined the neuroanatomical and subcellular distribution of 
CHT.  The first anatomical visualization of CHT distribution was performed using 
[3H]HC-3 autoradiography that was validated by lesioning of cholinergic pathways 
(Pascual et al., 1991; Rainbow et al., 1984; Rossner et al., 1995).  This approach 
however, did not permit resolution of CHT at the synaptic level (Rainbow et al., 1984; 
Rossner et al., 1995).  Although these early studies allowed for the visualization of 
specific regions of CHT expression, these results are somewhat difficult to interpret as 
substantial evidence exists that HC-3 binding to CHT has been shown to be dependent 
upon CHT availability and relative activity of cholinergic neurons (Lowenstein and 
Coyle, 1986). Studies by Blakely and colleagues, utilizing CHT-specific antibodies, 
confirmed the localization of CHT to cholinergic neurons in addition to its colocalization 
with vesicular acetylcholine transferase (VAChT) in rodent brain preparations (Ferguson 
et al., 2003), providing further support that CHT was involved in support of ACh 
synthesis.  Additional studies conducted at the rodent NMJ and in primate brain 
supported these conclusions (Misawa et al., 2001) (Kus et al., 2003).   
Examination of the anatomical distribution of CHT immunoreactivity identified in 
a number of brain regions known to have cholinergic inputs such as midbrain, brainstem, 
spinal cord, hippocampus, striatum and cortex (Kobayashi et al., 2002; Lips et al., 2002; 
Misawa et al., 2001).  Northern blotting of various regions of mouse brain confirmed 
presence of CHT mRNA in brain regions with cholinergic projections, but that CHT 
mRNA was lacking in regions lacking cholinergic neurons such as the cerebellum 
(Apparsundaram et al., 2001).  CHT has also been identified at the neuromuscular 
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junction (Nakata et al., 2004).  Within the peripheral nervous system, CHT 
immunoreactivity has been identified within autonomic nervous system (ANS) 
projections of the parasympathetic nervous system branch (PNS) innervating the heart 
(Hoover et al., 2003; Mabe AM, 2006).  These studies demonstrated that CHT expression 
was limited to cardiac nodal tissue, including the sinoatrial (SA) and atrioventricular 
(AV) nodes, regions shown to have PNS innervation via the vagus nerve (Hoover et al., 
2003; Loffelholz and Pappano, 1985) (Figure 4).   
Additionally CHT immunoreactivity has been identified in non-neuronal cell 
types including epithelial skin cells, tracheal epithelium and urinary bladder epithelium 
(Hanna-Mitchell et al., 2007; Pfeil et al., 2003a; Pfeil et al., 2003b).  Using 
immunohistochemistry and CHT mRNA expression, CHT has been detected in tracheal 
epithelial cells by in-situ hybridization and has been suspected in regulating ACh after 
breakdown at the luminal service hence governing tracheal function of ciliated cells (Lips 
et al., 2007; Pfeil et al., 2003b).   In the urinary bladder, CHT is expressed in epithelial 
cells in addition to ChAT, however VAChT could not be identified in these cells possibly 
due to sensitivity issues (Hanna-Mitchell et al., 2007).  CHT was found that urinary 
bladder cells also express another plasma membrane transporter, organic cation 
transporter (OCT3) that may also be involved in the release of ACh from non-neuronal 
cells, however the interaction of CHT with the OCT transporter remains to be elucidated 
(Hanna-Mitchell et al., 2007).  Similarly, CHT immunoreactivity and expression has been 
demonstrated in human keratinocytes, though a role of CHT in skin cells remains to be 
clarified (Pfeil et al., 2003a). 
A CHT D CHT
B
VAChT
E CHT (RA)
C               CHT+VAChT F               CHT (LV)
Figure 4. Immunoreactivy of CHT and VAChT in mouse heart. (A-E)
Confocal images of intrinsic cardiac neurons (ICNs) double labeled for
CHT (A), VAChT (B) and the overlay (C) show cholinergic localization
in mouse nodal tissue. Open arrows indicate atrial nerve fibers.
Colocalization of CHT and VAChT in atrial nerve fibers. (D-E)
Immunoreactivity of CHT in sinus node, atrium and ventricle of mouse
heart. Distribution of CHT is highest in nodal tissue, but diminishes in
right atrial (RA) and left ventricular (LV) tissue. Adapted from Hoover et
al. (2008, 2006).
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Within the cardiovascular system, non-neuronal expression of CHT has been 
demonstrated in rat and human arterial vascular smooth muscle wall lending evidence to  
a role of a non-neuronal, intrinsic cholinergic system within the vasculature (Lips et al., 
2003).  Additional evidence for a non-neuronal, vascular cholinergic system are findings 
that the arterial and microvascular endothelial cells release ACh and have been shown to 
express ChAT and VAChT (Haberberger et al., 2000; Haberberger et al., 2002; Milner et 
al., 1989).   
Lastly, the cholinergic nervous system has been implicated in the modulation of 
the immune response (Tayebati et al., 2002).  Several studies have confirmed the 
presence of cholinergic markers within T-cell lymphocytes including mAChRs, nAChRs, 
ChAT, CHT and AChE (Kawashima and Fujii, 2004).  Stimulation of T-cell activation 
has been shown to enhance lymphocytic cholinergic transmission by upregulation of 
ChAT, mediated by the nAChRs, thus implicating a role of cholinergic transmission 
modulating the immune response (Kawashima and Fujii, 2003b).  Together, these 
findings reveal a broader role for CHT-supported cholinergic signaling than previously 
suspected. 
To provide further resolution of the subcellular localization of CHT, immuno-EM 
microscopy analysis was performed in cholinergic neurons of the CNS and 
neuromuscular junction (NMJ) preparations.  Significant CHT labeling was visualized at 
the presynaptic level in both CNS and the NMJ (Ferguson et al., 2003) (Figure 5).  
Surprisingly, there was a predominance of CHT labeling associated with the intracellular 
presynaptic vesicles (Ferguson et al., 2003).  Immuno-EM labeling of CHT at cholinergic  
Figure. 5. Colocalization of CHT with VAChT at presynaptic
terminals in cholinergic neurons. (A) Confocal imaging of CHT
immunoreactivity in ventral horn of mouse spinal cord (scale bar = 20
µm). (B) VAChT immunoreactivity in similar cell bodies as CHT. (C)
Overlapping distribution of CHT and VAChT confirming colocalization.
(D) Immuno-EM with CHT-specific antibodies with arrows showing
CHT is localized in the presynpatic neuron. (E) Cell body of cholinergic
neuron with CHT immunoreactivity identified in the rough endoplasmic
reticulum (scale = 1µm). Data adapted from Ferguson and Blakely
(2004).
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presynaptic terminals was found to be consistent with the known morphology of 
cholinergic terminals (Gilmor et al., 1996).   
The identification of the presynaptic vesicular localization of CHT provided 
evidence that “pools” of CHT existed in cholinergic neurons and provided a mechanism 
by which CHT Vmax can be increased following cholinergic neuron activation (Kuhar and 
Murrin, 1978).  To confirm the localization of CHT in presynaptic cholinergic neurons, 
subcellular fractionation experiments of synaptosomal preparations from whole mouse 
brain, using high-speed gradient centrifugation was utilized.  Similar to the EM studies, 
CHT was enriched in the P2 fraction with the majority of CHT enrichment found within 
the LP2 fractions along with other presynaptic vesicular proteins such as synaptophysin 
and VAChT (Eiden, 2000; Ferguson et al., 2003) (Figure 6).  These subcellular 
localization studies along with synaptic vesicle immuno-isolation and EM vesicle 
analysis suggest a linkage of CHT to distinct vesicular pools containing VAChT and that 
fuse with the membrane during increased rates of cholinergic firing, therefore, CHT can 
possibly delivered to the plasma surface coupled to ACh release permitting activity-
dependent choline recycling.   
Activity Dependent Regulation of CHT 
 Multiple studies have demonstrated an intimate link between the Vmax of CHT-
mediated HACU and the Bmax of [3H]HC-3 binding coupled to changes in cholinergic 
activity (Atweh et al., 1975; Ferguson et al., 2004; Lowenstein and Coyle, 1986). 
Previous work showed that CHT-mediated HACU sustained ACh synthesis and release 
during persistent and prolonged stimulation (Birks and Macintosh, 1961; Maire and 
Wurtman, 1985), and as noted during steady state, the majority of CHT resides on  
Figure 6. Subcellular fraction of whole mouse brain shows CHT
localization to presynaptic vesicles. Whole mouse brain subcellular
fractionation by differential centrifugation shows CHT enrichment in the
LP2 fraction consistent with other presynaptic vesicle markers, VAChT
and synaptophysin (Syp). Adapted from Ferguson et al. (2003).
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VAChT containing presynaptic vesicles (Ferguson et al., 2003). The uptake of choline 
demonstrates saturation at low micromolar concentrations, therefore in order to increase 
choline uptake, an increased number of CHT’s at the plasma surface would be required.   
Depolarization of synaptosomes (e.g. high K+) or electrical stimulation mimicking 
increased cholinergic firing rates have demonstrated an increase in the CHT-mediated 
uptake (Vmax) (Collier et al., 1983; Simon and Kuhar, 1975) and that these changes can be 
blocked by pretreatment of hippocampal synaptosomes with botulinum toxin C, known to 
inhibit vesicular release of neurotransmitter (Blasi et al., 1993).  Synaptosomal 
preparations made from rat hippocampus also showed that pharmacologic treatments 
leading to a decrease in ACh release resulted in a concomitant decrease in CHT Vmax 
(Atweh et al., 1975).  These changes observed in CHT Vmax secondary to an increase in 
cholinergic activation have been shown to be coupled to an increase [3H]HC-3 binding 
demonstrating that the increase in Vmax was associated with an increase in the surface 
density of CHT (Bmax) in stimulated membrane preparations and in striatal slices 
(Ferguson et al., 2003; Lowenstein and Coyle, 1986; Saltarelli et al., 1987).  These 
findings have been eloquently replicated in in vivo studies whereby mice exposed to 
various learning paradigms exhibited an increase in CHT uptake and expression 
(Apparsundaram et al., 2005).   
Whereas in vitro (Ferguson et al., 2003) and in vivo (Apparsundaram et al., 2005) 
studies demonstrated that CHT is inserted into the plasma membrane by a fraction of the 
same VAChT-positive vesicles that mediate ACh release, questions still arise as to the 
mechanisms regulating CHT sorting at the surface.  Additionally, while depolarization of 
synaptosomes results in immediate increases in ACh release, changes in CHT function 
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require several minutes of stimulation indicating a temporal difference in CHT regulation 
upon insertion into the plasma membrane (Ferguson et al., 2003; Murrin et al., 1977). 
These studies demonstrate that the trafficking and activation of CHT is coupled to the 
activation state of cholinergic transmission but that other mechanisms exist regulating 
CHT function at the surface. 
Less is known about the regulated recycling and plasma membrane recruitment of 
CHT.  Since CHT and VAChT has been shown to be collocated on synaptic vesicles and 
both share a common acidic residue-flanked dileucine motif in their cytoplasmic C-
terminal, it has been proposed that CHT recycling occurs via a clathrin-dependent 
pathway (Ribeiro et al., 2007).  Thus, when COS-7 cells were cotransfected with a 
dominant-negative K44A dynamin I mutant, constituative endocytosis of CHT from the 
surface was inhibited (Tan et al., 1998).  Similarly, Ribeiro, et al. demonstrated that the 
presence of CHT at the surface is limited by endocytosis of the transporter in clathrin-
coated vesicles in a dileucine-dependent mechanism (Ribeiro et al., 2006).  K+-evoked 
depolarization studies using HEK-293 and SH-SY5Y cells demonstrated that the activity-
dependent increase in CHT at the plasma membrane is regulated by two mechanisms 
involving increased externalization of the intracellular CHT pool and recruitment of 
additional intracellular CHT from the recycling pool, indicating two separate synaptic 
vesicular pools of CHT translocated to the surface during increased cholinergic demands 
(Ribeiro et al., 2007).  The mechanisms regulating these various CHT-positive vesicular 
pools to the surface and their endocytosis by adaptor proteins and C-terminal motifs are a 
current area of investigation (Ruggiero AM, personal communication). 
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The Human Choline Transporter (CHT) 
Genetics of the Choline Transporter 
The human CHT (hCHT) is a member of the SLC5A gene family (designated 
SLC5A7) of the Na+-dependent transporters and is similar in structure to the Na+-
dependent glucose transporter (SGLT) that is the best characterized transporter in this 
family of ≈80 transporters (Wright et al., 1992).  The human CHT gene, has been mapped 
to chromosome 2q12 (chromosome 17, mice), spanning 25kb of genomic sequence 
(Figure 7A) (Ferguson and Blakely, 2004; Okuda and Haga, 2000).  Hydrophilicity 
analysis and topology prediction algorithms predict a protein with 13 transmembrane 
domains (TMDs) containing a short extracellular N-terminus and long intracellular C-
terminus, that exhibit 93%, 98% and 52% amino acid sequence homology to murine, rat 
and C. elegans CHT proteins respectively (Figure 7B) (Ferguson et al., 2003; Okuda et 
al., 2000).  Within the proposed topology of CHT, a consensus site for N-liked 
glycosylation has been identified at residue N301 in the fourth extracellular loop.  The 
intracellular C-terminal tail possess several canonical motifs for serine and threonine 
phosphorylation sites that may be important for CHT regulation and trafficking of CHT 
to the cell surface (Ferguson et al., 2003; Gates et al., 2004). 
 Within the initiation of our studies, there had been few studies examining the 
polymorphic status of the CHT gene, though one report described a hypomorphic coding 
variant that might influence cholinergic traits or influence risk for cholinergic-mediated  
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Figure 7. CHT gene and protein structures. (A) The human CHT gene is
located on chromosome 2 and contains 9 exons. (B) The mCHT cDNA
encodes a protein of 580 amino acids, with a molecular mass of
approximately 63 kDa. Analysis of the amino acid sequence predicts a
topology of thirteen transmembrane domains, an extracellular consensus site
for N-linked glycosylation, and several cytoplasmic protein kinase A (PKA)
d t i ki C (PKC) h h l ti it (A d t lan pro e n nase p osp ory a on s es pparsun aram e a .
2001a). Adapted from Ferguson and Blakely (2004).
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disorders (Okuda et al., 2002).  In their study, Okuda et al., identified a non-synonymous 
single nucleotide polymorphism (SNP) residing in exon 3 at nucleotide 265 (A265G, 
rs1013940) that results in an isoleucine to valine amino acid substitution at position 89  
(Ile89Val) within TM3 of the expressed protein (Okuda et al., 2002) (Figure 8A). This 
study reported a frequency of the Ile89Val allele of 6% in a healthy Ashkenazi Jewish 
population (Okuda et al., 2002), findings that were subsequently validated in a larger 
panel by our group (Hahn et al., 2008) 
 Functional characterization of the Ile89Val variant in transfected COS-7 and 
HEK-293 cells demonstrated a ≈40-50% reduction in the transport velocity (Vmax) for 
choline for the mutant (Val) versus the wildtype (Ile), whereas the affinity for choline 
was not changed (Figure 8B) (Okuda et al., 2002).  While the reduction in Vmax could be 
explained by a decrease in the cell surface expression of the CHT protein; Okuda et al., 
using both biotinylation and HC-3 surface binding, demonstrated that the reduction in 
Vmax was not attributed to a reduction in the surface expression of CHT (Okuda et al., 
2002).  Although an Ile to Val represents a conservative change in amino acid 
substitution, this variant occurs in an exonic region displaying a high degree of sequence 
conservation among various species indicating that this region plays a significant role in 
the function of CHT (Figure 9A).  Of the 82 reported SNPs within the CHT locus, 
including the Ile89Val variant, none within the initiation of this thesis had been explored 
for contributions to human disease.   
Recently, another polymorphism originally designated as a component of the 
CHT 3’UTR (+4067 G/T; rs333229) was identified and found to be associated with 
altered cholinergic tone in healthy volunteers (Neumann et al., 2005).  Our current  
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Figure 8. CHT gene SNPs and effects of Ile89Val on choline uptake in
transfected cells. (A) The human CHT gene is located on chromosome 2
and contains 9 exons. Two SNPs (+265A/G and the 3’SNP) have been
associated to altered CHT function. (B) [3H]choline uptake (inhibited by
1μM HC-3) in transiently transfected COS-7 cells expressing WT or I89V
tconstructs. Saturation kinetics of WT and I89V CHT in transfected cells
h l ffi it f h li (K ) b t di i i h d i l t ks ows norma a n y or c o ne m , u m n s e max ma up a e
(Vmax) (Km: WT=2.8±0.1; I89V=3.0±0.3 and Vmax: WT=102±9;
I89V=55±6, P=0.01). Adapted from Okuda (2003).
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Figure 9. Sequence alignment of hCHT exon 3 (Ile89Val) and haplotype
map of the hCHT gene. (A) Sequence alignment of CHT gene exon 3
shows significant sequence homology in mammalian CHT gene. (B)
Linkage disequilibrium estimates for the reported SNPs within the hCHT
gene identifies 4 distinct haplotypes (Okuda et al 2002) Adapted from. . .
International HapMap Project 2004.
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genomic analysis place this variant 3’ of the predicted polyadenylation site and could not 
be identified with deposited ESTs, and thus will be referred to as the CHT 3’SNP (Figure 
7A).  Although the functional consequence of this SNP remains unclear, this study found  
the 3’SNP minor allele to positively correlate with the high frequency (HF) component of 
heart rate variability (HRV), a measure of vagal regulation of heart rate, in healthy 
volunteers.  Using fMRI and HRV measurements, the 3’SNP, was recently shown to be 
associated with a decrease in corticolimbic reactivity in Brodmann Areas 6, 9 and 46, 
which also correlated to HRV (Neumann et al., 2006).  These studies suggest that the 
CHT 3’SNP has, or is linked to other variants functional effects associated with an 
increased cholinergic tone and contributes to the corticolimibic and autonomic circuitry 
mediating behavioral and physiologic arousal.  Though 3’UTR variants are hypothesized 
to disrupt mRNA stability, further studies are required to determine the actual impact that 
this 3’SNP variant has on CHT expression.  Additionally, further studies are required to 
determine the impact of this 3’SNP variant in relation to the non-synonymous CHT 
variant, Ile89Val.  Importantly, these variants exist on distinct haplotypes. The high 
minor allele frequency of the 3’SNP variant (22%), allows determination of its impact in 
relatively modest size cohort studies (Figure 9B).  To date, neither the Ile89Val nor the 
3’SNP CHT variants have been examined in large numbers of subjects with various 
diseases which cholinergic dysregulation may have an impact on severity of is associated 
with overall symptom severity in a small study of patients with major depression disorder 
(MDD) (Hahn et al., 2008). 
  
 24
Role of CHT in Mammalian Physiology 
 Whereas the impact of disruptions in cholinergic function on mammalian 
physiology has been well studied, many of these studies have focused on presynaptic 
release of ACh or post-synaptic receptor effects.  For example, exposure of animals to 
irreversible AChE inhibitors that results in a large increase of ACh in the synaptic cleft 
often results in lethality.  In humans, disruption in cholinergic transmission has been 
implicated in many neurologic, cardiovascular, autoimmune and psychiatric disorders 
(Lefkowitz, 1996; Sarter and Parikh, 2005).   A few studies utilizing HC-3 had 
demonstrated a physiologic lethality due to antagonism of CHT (Jones and 
Kwanbunbumpen, 1970).  Until recently however, no studies had been conducted 
examining the role of the genetic loss of the presynaptic CHT.  Given the role of the CHT 
in the biosynthesis of ACh and maintenance of cholinergic tone, disruptions in CHT 
function may contribute to these disorders. 
 To examine the role of a genetic loss of CHT on murine behavior and physiology, 
a homozygous CHT knockout mouse (CHT-/-) was developed (Bazalakova et al., 2003; 
Ferguson et al., 2004).  CHT-/- mouse pups are smaller and appear cyanotic at birth 
(Figure 10A), and are devoid of expressed CHT.  As a consequence, these mice are 
deficient in functioning CHT, displaying loss of CHT-mediated HACU (Figure 10B) and 
exhibit a time-dependent loss of both spontaneous and evoked ACh induced responses at 
the NMJ (Figure 10C) (Ferguson et al., 2004).  The loss of functioning CHT in CHT-/- 
mice results in postnatal lethality, possibly due to respiratory arrest as these mice become 
cyanotic, exhibit no alveolar inflation and die within 1 hour after birth (Ferguson et al., 
2004).   Additionally CHT-/- mice display histological changes at the NMJ as  
Figure 10. CHT-/- mice demonstrate that CHT-mediated choline uptake
is essential for postnatal viability. (A) While being equal in size, the CHT-
/- pup is visibly cyanotic vs. the CHT+/+ pup (photo take 30 min post-
birth). (B) Loss of HC-3 (1 µM) sensitive choline uptake in synaptosome
from CHT-/- mice vs. CHT+/+ mice. Conversely, [3H]GABA uptake was
not significantly different (P=0.2). (C) Electrophysiologic tracings of ACh
l f CHT / d CHT / NMJ d i k d EPP ( l) dre ease rom + + an + - s ur ng evo e top pane an
spontaneous EPP (bottom panel) at 1hr and 4hrs. Notice loss of evoked and
spontaneous EPPs in CHT-/- mice by 4 hours. (D) CHT protein expression
is reduced in whole brain extracts from CHT+/- mice compared to CHT+/+
mice, although synaptosomal preparations (E) show CHT-mediated HACU
kinetics (Kd and Vmax) are similar between genotypes. Adapted from
Ferguson et al (2004) and Bazalakova et al (2008), . , .
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demonstrated by changes in nAChR distribution with increased clusters of receptors, 
possibly to compensate for reductions in ACh availability (Ferguson et al., 2004). 
 The postnatal lethality phenotype of the CHT-/- mice limits further investigation 
into the genetic influences of CHT to cholinergic tone in other organ systems.   
Fortunately, heterozygous mice (CHT+/-) are both viable and seemingly healthy 
compared to CHT+/+ mice, yet express half the levels of CHT protein (Figure 10D).  
When compared to CHT+/+ mice, CHT+/- mice surprisingly exhibit equivalent choline 
uptake (Vmax) accompanied by similar levels of [3H]HC-3 binding (Bmax) (Figure 10E) 
(Ferguson et al., 2004).  These similarities in both carrier-mediated HACU and HC-3 
binding densities between both genotypes corroborates an ability of cholinergic neurons 
to detect changes during ACh demand and mobilize reserves of CHT vesicular pools to 
the plasma membrane (Ferguson et al., 2004).  Although the CHT+/- mice display similar 
CHT Vmax, these mice display an increased sensitivity to sub-lethal i.p. doses of HC-3 
(Figure 11A), demonstrating a lack of CHT reserves that cannot meet sustained, capable 
of meeting increases in cholinergic demand.  Similarly, during sustained treadmill 
exercise, CHT+/- mice show impairments in duration and speed compared to CHT+/+ 
mice (Figure 11B and C) (Bazalakova et al., 2007).  Further analysis is required to 
determine the impact this reduced CHT capacity has on functions requiring continuous 
cholinergic tone such as behavior, learning and autonomic regulation. 
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Figure 11. Genetic loss of CHT-mediated HACU produces a physiologic
phenotype in CHT+/- mice. (A) CHT+/- mice increased sensitivity to sub-
lethal doses of HC-3 vs. CHT+/+ mice. (B) CHT+/- show impaired exercise
capacity with deficits in acute (speed) tolerance and endurance (C) on
treadmill tests (*P<0.01, ***P<0.001). Values represent ±SEM. Adapted
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from Ferguson, et al. (2004) and Bazalakova, et al. (2008)
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Cholinergic Transmission in Cardiovascular and Behavioral Function 
Cholinergic Transmission and Cardiovascular Function 
 The regulation of many visceral physiological functions within the body is 
mediated by the autonomic nervous system (ANS).  This system is responsible for the 
regulation of heart rate, blood pressure, gastrointestinal motility, secretion, body 
temperature and many other functions (Lefkowitz, 1996).  To achieve dynamic control 
these functions, the ANS is subdivided into the sympathetic nervous system (SNS) and 
the parasympathetic nervous system (PNS) (Figure 2).  The ANS is predominantly 
activated by neural centers located within the spinal cord, brain stem and cerebral cortex 
(Guyton, 1992).   The SNS, known colloquially as the “fight-or-flight” system as it 
mediates increases in those physiologic responses required by the organism to respond 
quickly such as heart rate and respirations (Lefkowitz et al., 2000).  Conversely, the PNS 
is characterized as the “rest-and-digest” system and mediates more vegetative functions 
such as digestion, salivation and urination (Lefkowitz, 1996).    
The autonomic nervous system plays a major role in regulating heart rate and the 
short-term regulation of blood pressure.  The basic neurotransmitters, receptor systems 
and the effects mediated by the SNS and PNS are shown in (Table 1).  Sympathetic 
regulation of the heart is mediated by the β1 adrenergic receptor (β1AR).  The β1 is a 
member of the G protein-coupled receptor (GPCR) family and is coupled to the Gs 
heterotrimeric protein family (Lefkowitz, 1996).  Stimulation of β1ARs results in an 
increase in adenylyl cyclase, activating the cAMP-PKA-dependent signaling pathways.   
Activation of cardiac β1ARs results in an increase in chronotropic (heart rate) and 
ionotropic (contractile) properties of the heart (Lefkowitz, 1996).  Conversely,  
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parasympathetic regulation of the heart is primarily mediated by M2-muscarininc 
acetylcholine receptor (M2AChR) (Caulfield, 1993).  The M2AChR is also a member of 
the GPCR superfamily, and is coupled to the Gi/o heterotrimeric protein family (Caulfield, 
1993; Rouse et al., 1997).  Agonist stimulation of the M2AChR activates the Gi/o protein 
resulting in an inhibitory effect on adenylyl cyclase, counteracting cAMP-PKA-
dependent signaling pathways (Wettschureck and Offermanns, 2005).  Activation of the 
M2AChR coupled Gi/o protein also produces a direct increase in K+-channel (IK) 
activation, resulting in a hyperpolarization of both the SA and AV nodes (Szabo and 
Otero, 1989; Valenzuela et al., 1997).  Additionally, the Gβγ subunit of Gi/o heterotrimeric 
protein can directly activate the muscarinic-gated-K+-channels (IKACh) within cardiac 
nodal tissue, allowing for vagal regulation of chronotropic effects of the heart (Logothetis 
et al., 1988; Zhu et al., 2001).   
 Few studies have examined the role of CHT-mediated HACU in 
cardiovascular regulation.  Given the role of CHT in supporting cholinergic tone, it 
would be expected that alterations in CHT function contribute to diminished vagal tone to 
the heart resulting in cardiovascular dysfunction.  As previously mentioned, CHT was 
found to be co-expressed with another protein marker, neurturin (NRTN), a marker 
required for the development of normal cholinergic innervation to the heart, in nodal 
tissue of murine hearts, demonstrating the presence of CHT in regions of the heart 
responsible for chronotropic effects (Mabe AM, 2006).  Similarly, the finding of CHT 
expression in non-neuronal vascular endothelial tissue raises the possibility of cholinergic 
function mediated vascular tone (Haberberger et al., 2000).   
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In human cardiovascular disorders, though no specific disorder has been 
attributed to alterations in CHT function, the impact of diminished cholinergic tone in 
cardiovascular mortality and morbidity has been well documented (Barron and Lesh, 
1996; Fox et al., 2007).  Cholinergic innervation of the heart is localized to nodal areas 
and most commonly associated with reduction in HR, where it contributes to the overall 
autonomic tone of the heart, thereby influencing parameters such as acute variability of 
heart rate (HRV), baroreceptor sensitivity (BRS) and resting HR (Eckberg et al., 1971; 
Stein and Kleiger, 1999; Taylor, 1994).  Depression of BRS and HRV due to diminished 
parasympathetic tone has been associated with increased mortality due to sudden cardiac 
death in both humans and animal models of myocardial infarction (MI) after ischemic 
episodes (Barron and Lesh, 1996; Vanoli et al., 1991).  Using frequency-domain analysis, 
HRV can be shown to display two primary components, a low frequency (LF) and high 
frequency (HF) component, with the HF component of HRV in humans reflecting tonic 
vagal activity (Pieper, 1995).  Frequency-domain analysis of HRV has been used in 
various clinical settings and has been shown to be a powerful predictor of adverse 
prognosis in patients with congestive heart failure (CHF), MI, coronary artery disease 
(CAD) and life threatening ventricular arrhythmias post-MI (Bigger, 1992; Binkley, 
1991; Lombardi, 1996; Norris et al., 2006; Rich, 1988).   
Unlike HRV, baroreceptor sensitivity (BRS) is a vagally-mediated response to an 
increase in peripheral vascular resistance and is responsible for acute regulation of HR 
and blood pressure (BP) (Taylor, 1994).  In subjects with normal BRS, a rapid rise in 
arterial blood pressure elicits a vagally-mediated reduction in HR achieved by both an 
increase in direct parasympathetic tone and an indirect blunting of sympathetic activation 
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(Eckberg DL, 1992).  Similar to HRV, BRS has also been shown to be a strong 
prognostic indicator of mortality post-MI, with patients having a reduced BRS 
demonstrating a higher mortality rate (La Rovere, 2001).  The utility of monitoring BRS 
has been shown in both human and animal models of MI (Schwartz et al., 1988).  Several 
cardiovascular disorders including hypertension (HTN), CAD, MI and HF, have been 
shown to be accompanied by decreased BRS (La Rovere et al., 2008).  This imbalance in 
the sympathetic-vagal outflow to the heart results in a chronic increase in sympathetic 
tone and possibly contributes to progression of the cardiovascular disorder and end-organ 
damage (Eckberg DL, 1992).   
Other cardiac parameters regulated by parasympathetic tone include resting HR 
and HR recovery following exercise.  Several studies have shown that an elevated resting 
HR is associated with and increase in BP and can serve as a precursor to the development 
of chronic HTN, atherosclerosis and other cardiovascular events (Palatini and Julius, 
1999).  The Framingham Study showed that an increased resting HR was associated with 
an increase in mortality at 2 years post-diagnosis (Gillman et al., 1993).  Tachycardia in 
hypertension is associated with decreased parasympathetic tone and increased 
sympathetic tone, contributing further dysfunction of cardiovascular physiology (Palatini 
and Julius, 2004).  Regulation of HR by the administration of medications that either 
block an overactive sympathetic tone (e.g. β-blockers; propranolol) or increase vagal tone 
(e.g. angiotensin converting enzyme inhibitors) have become the mainstays of treatment 
in patients with MI and HF (Lanza et al., 2006; Smith et al., 2005).  These medications 
have been shown to improve mortality associated with these conditions (Fox et al., 2007).  
Additionally, early recovery in HR after exercise has been shown to be mediated by 
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parasympathetic activation, and to be a predictor of ventricular susceptibility to fatal 
arrhythmias after MI (Pierpont et al., 2000; Smith et al., 2005).  Similar to BRS and 
HRV, HR recovery (HRR) after exercise has also been shown to be an independent 
predictor of mortality in a wide range of patients (Cole et al., 1999; Curfman and Hillis, 
2003).   
In patients with chronically elevated resting HR and HF, studies have shown that 
the parasympathetic nervous system appears to be attenuated (La Rovere et al., 1994).  
Although most studies have not demonstrated changes in M2AChR receptors or coupling 
to Gi/o inhibitor G-proteins, in patients with HF, such changes may serve to be beneficial 
to the failing heart by promoting increased sympathetic tone preserving cardiac output 
(CO) (Brodde et al., 1998; Brodde and Leineweber, 2004).  However in HF studies 
conducted in mongrel dogs, HF induced by rapid ventricular pacing resulted in an 
increase in M2AChR and a decrease in AChE activity, thus demonstrating the cholinergic 
nervous systems attempt to reduce the damage secondary to sympathetic overactivation 
(Dunlap et al., 2003).  Together, these data support the hypothesis that disruptions to 
CHT function may diminish ACh transmission of the vagal innervation to the heart and 
thus produce alterations in resting HR, HRV, BRS and HRR, lending to worsening of 
cardiac function and contribute to cardiovascular disorders.   
Cholinergic Transmission and Behavioral Function 
 Within the mammalian CNS, cholinergic neurons sustain or modulate diverse and 
complex behaviors such as attention, arousal, memory and reward (Perry et al., 1999; 
Sarter and Parikh, 2005).  Disorders such as Alzheimer’s Disease (AD), a degenerative 
disorder of the basal forebrain cholinergic neurons, is thought to be the cause of the 
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dementia related cognitive deficits associated with the disorder (Whitehouse et al., 1982).  
Therapies such as acetylcholinesterase inhibitors (AChEI), that prevent the hydrolysis of 
ACh have been shown to provide improvement in cognitive decline associated with AD 
(Giacobini, 2000).  Similar alterations in cholinergic function underlying the attentional 
and cognitive impairments associated with psychiatric disorders, such as attention deficit 
hyperactivity disorder (ADHD) (Beane and Marrocco, 2004), major depressive disorder 
(MDD) (Vakalopoulos, 2007) and delirium (Hshieh et al., 2008) have been hypothesized.   
 Attenuated cholinergic regulation of catecholaminergic transmission has been 
studied in a number of psychiatric disorders and novel therapeutics exhibiting pro-
cholinergic effects have demonstrated efficacy in the treatment of several 
neuropsychiatric disorders.  Dysfunctional activation of cholinergic inputs in dopamine 
regulation have been hypothesized to influence some of the movement deficits and 
negative or vegetative symptoms of psychiatric disorders such as schizophrenia and 
major depressive disorder (Laruelle et al., 2003; Lieberman et al., 2008).  Modulation of 
cholinergic transmission by novel atypical antipsychotics have been implicated in the 
improvement of extrapyramidal symptoms, negative symptoms and cognitive impairment 
associated with schizophrenia (Gray and Roth, 2007).  Additionally, several pro-
cholinergic therapeutic agents increasing ACh transmission via inhibition of hydrolysis 
(Guillem et al., 2006) or direct acting agents targets specific muscarinic receptor subtypes 
(Langmead et al., 2008). 
 
Murine Models of Cholinergic Dysfunction in Cardiovascular and Behavioral Disorders 
Murine Models of Cholinergic Dysfunction in Cardiovascular Disorders 
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 The murine cardiovascular system has received considerable attention due to the 
number of genetic manipulations and implantable telemetric devices available to study 
mammalian cardiovascular function in vivo.  Several of the studies have examined the 
role of genetic manipulations on enzymes necessary for the biosynthesis of and 
degradation of neurotransmitters, transport proteins involved in uptake and recycling of 
neurotransmitters and receptor subtypes mediating the post-synaptic responses involved 
in autonomic function (Janssen and Smits, 2002).   Other studies have been conducted 
examining the role of post-synaptic receptor signaling molecules or the ion channels 
mediating the autonomic stimulation (Gehrmann and Berul, 2000). 
 Within the sympathetic branch of the ANS, many of the studies examining the 
impact of nullizygous genotypes in enzymes involved in catecholamine biosynthetic 
pathways have provided limited cardiovascular information as many of these mice 
exhibited profound sympathetic deficits and die perinatally (Kobayashi et al., 1995; 
Thomas et al., 1998).  Studies have also been conducted in mice deficient in 
catecholamine metabolism such as catechol-O-methyltransferase (COMT) and 
monoamine oxidase (MAO), however these mice have been evaluated primarily for their 
behavioral and neurological deficits due to elevated adrenergic tone (Cases et al., 1998; 
Grimsby et al., 1997).  Although the cardiovascular phenotypes were not evaluated in 
these mice, there have been a number of studies linking stress response and 
cardiovascular disease (Farah et al., 2004; Keller et al., 2006).  
 The post-synaptic adrenergic receptors and their signaling molecules have been 
widely studied in the mouse.  The adrenergic receptor family consists of three β-
adrenergic receptor subtypes (β1, β2, β3), three α2-aderenergic subtypes (α2A, α2B, α2C), 
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and three α1-adrenergic subtypes (α1A, α1B, α1D) (Lefkowitz, 1996).  The α1-receptors 
have been primarily studied with respect to the vasculature as these receptors mediate 
vasoconstriction (Lefkowitz, 1996).  The α2- and β-receptors have been studied within 
the CNS, renal vasculature and the heart (Janssen and Smits, 2002; Lefkowitz, 1996).    
 The primary receptors mediating the ANS regulation of the cardiovasculature are 
the β- and α-adrenergic receptors.  Several transgenic mouse models of cardiovascular 
disease have been created from a variety of different mouse strains.  The cardiovascular 
parameters of normal WT mice from the various mouse strains have been summarized in 
Table 2.  Transgenic murine models of autonomic receptors have either included 
knockouts or overexpressors particularly focusing on β1 and β2, or α2-adrenergic 
receptors in order to determine the impact of these receptor systems on the 
cardiovasculature.  The α2A-receptor subtype is highly expressed within the CNS and 
serves as the principle receptor mediating the central sympathoinhibitory effects of 
pharmacologic agonists such as clonidine resulting in hypotension and bradycardia (Hein 
et al., 1999; Makaritsis et al., 1999).  Studies in α2A-knockout mice, demonstrate elevated 
HR and increased plasma and tissue levels of NE indicating a hyperadrenergic state.   
 The β1-adrenergic receptor subtype has been shown to mediate the chronotropic 
(heart rate) and ionotropic (contraction) of the heart, whereas the β2-adrenergic receptor  
subtype has been shown to mediate vascular smooth muscle relaxation and to oppose the 
effects of β1 over activation (Lefkowitz et al., 2000; Liggett et al., 2000).  In studies 
conducted in β1 and β2 knockout mice, resting HR and BP were surprisingly similar to 
wildtype mice (Rohrer et al., 1999).  In β1-knockout mice, chronotropic activation with 
isoproterenol was blunted, however BRS reflex was preserved demonstrating that within  
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the murine cardiovascularture, the β1-adrenergic receptor was responsible for mediating 
the chronotropic effects and that the parasympathetic nervous system was in tact as 
evidenced by unaltered BRS tone (Rohrer et al., 1998).  However, in β1/β2- double 
knockout mice, mAChR receptor density was significantly reduced, possibly 
compensating for the loss of β1-adrenergic tone to the heart (Rohrer et al., 1998) in an 
attempt to preserve cardiac output.   
 In contrast to β-adrenergic receptor nullizygous mice, overexpression of β-
adrenergic receptors have produced some striking cardiovascular phenotypes.  In mice 
with a 5-fold overexpression of the β1-receptor, basal HR and contractile response was 
significantly enhanced, while HRV was significantly reduced (Engelhardt et al., 1999; 
Mansier et al., 1996) consistent with elevated sympathetic tone.  However, as these mice 
aged (>10 weeks), β1-ovexpressing mice exhibited marked deficits in cardiac function 
(reduced fractional shortening; evidence of reduced contractile efficiency) and associated 
ventricular hypertrophy (Engelhardt et al., 1999).  Similarly, β2-overexpressing mice 
exhibited increased basal cardiac function, however this effect appeared to be gene-dose 
related (Liggett et al., 2000).  In mice with a 60-fold ovexpression of β2, these mice 
exhibited an increase in cardiac function, however in mice with a 100-fold increase in β2-
expression, these mice develop a significant dilated cardiomyopathy and subsequent heart 
failure (Liggett et al., 2000).  The role of β2-adrenergic receptors mediating the inotropic 
support of the failing heart has also been identified in human models of heart failure 
(Bristow et al., 1986). 
 As noted above, the parasympathetic nervous system mediates the negative 
inotropic effects of heart rate regulation.  The primary receptor subtypes mediating 
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cholinergic (parasympathetic) regulation of the cardiovasculature are the nicotinic 
acetylcholine (nAChR) and muscarinic acetylcholine (mAChR) receptors.  Within the 
heart, the M2AChR is the primary receptor and activation of this subtype results in a 
reduction in HR mediated by the muscarinic-gated potassium channel (IKACh) (Gehrmann 
and Berul, 2000).  Though the M2AChR has been shown to be the principle muscarinic 
receptor subtype in the mammalian heart, and studies conducted in M1AChR knockout 
mice show that these mice exhibit normal basal cardiovascular features (Hardouin et al., 
2002).  However, treatment of mice with a selective M1 agonist (McN-A-343) failed to 
elicit increases in HR and MBP, indicating that the M1AChR mediates sympathetic 
postganglionic neurons to release NE (Hardouin et al., 2002).  Although the M1AChR has 
not been shown to be expressed in the mammalian heart, this muscarinic receptor subtype 
has been shown to be involved in ANS regulation of cardiovascular function (Hardouin et 
al., 2002).   
 In M2AChR knockout mice, basal HR and BP were similar to wildtype mice 
(LaCroix et al., 2008).  However, bolus injection of the β-adrenergic agonist, 
isoproterenol (ISO) induced a significant increase in HR, and chronic administration of 
ISO resulted in significantly impaired ventricular function (LaCroix et al., 2008).  
Similarly, M2AChR knockout mice were completely devoid of bradycardic activity 
during vagal nerve stimulation.  Although reduced vagal tone has been associated with 
higher basal HR and contributes to the development of various life-threatening 
arrhythmias, M2AChR knockout mice fail to demonstrate these effects (Fisher et al., 
2004).  This could be due the fact that mice tend to have lower vagal tone compared to 
larger mammals and are less susceptible to these abnormal cardiac conduction anomalies 
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(Fisher et al., 2004; Gehrmann and Berul, 2000).  In addition to HF with chronic ISO 
stimulation, M2AChR-/- mice also exhibited an increase in matrix metalloproteinase 
(MMP) activity, a protein associated with left ventricular dysfunction and hypertension 
(LaCroix et al., 2008).  Excessive MMP causes loss of normal collagen function within 
the cardiac extracellular matrix and it has been hypothesized that in addition to lowering 
HR, M2AChR stimulation also provides an inhibitory role on MMP via the ERK 1/2 
signaling pathway (LaCroix et al., 2008).   
 Several transgenic mouse lines have been developed examining the role of the 
enzymes involved in the biosynthesis and degradation of ACh.  In AChE-/- mice, a 
deficit in ACh metabolism produces a significant downregulation of M1 and M2AChRs 
within the CNS (Volpicelli-Daley et al., 2003).  These changes are mirrored by a 60% 
increase in CHT, likely an effort to increase substrate availability for loss of post-synaptic 
cholinergic responses (Bazalakova et al., 2007; Volpicelli-Daley et al., 2003).  
Additionally, these mice also display reduced sensitivity to mAChR stimulation-induced 
behavior.  However, none of these studies examined the impact of AChE loss on 
cardiovascular function.  It could be hypothesized that if AChE nullizygous produces a 
downregulation of mAChRs within the CNS, loss of M2AChRs within the heart would 
produce a hyperadrenergic state. 
 Within the ACh biosynthetic pathway, studies have been conducted in mice 
deficient for CHT, as well as the transporter responsible for providing substrate for ACh, 
(VAChT), and the enzyme choline acetyltransferase (ChAT), the enzyme responsible for 
conversion of choline and acetyl-CoA into ACh. ChAT-/- mice exhibit an inability to 
synthesize ACh and resulting in developmentally altered distribution of nAChRs at the 
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NMJ (Brandon et al., 2004).  The post-synaptic nAChRs in ChAT-/- mice exhibit wider 
distribution in comparison to WT littermates, possibly in an effort increase cholinergic 
tone.  The cardiovascular impact of a genetic loss of ChAT has not been examined in 
these transgenic mice (Brandon et al., 2004).  Although cardiovascular function in ChAT-
/- mice has not been directly examined, several studies have shown ChAT upregulation in 
the rostral ventrolateral medulla (RVLM) in animal models of hypertension (Lin and Li, 
1990) indicating that a compensatory upregulation of the cholinergic system can occur 
during hypertension.  These studies also showed an increase in central ACh content in 
hypertensive rats and has been hypothesized to contribute to the maintenance of 
hypertension in these rodent models (Kubo et al., 1995). 
In both CHT-/- and CHT+/- mice, similar reductions in CNS levels of ACh have 
also been identified (Bazalakova et al., 2007; Ferguson et al., 2004).  Similar to ChAT-/- 
mice, CHT-/- also show developmental alterations in nAChR distribution at the NMJ, 
however the overall pattern appears less severe (Ferguson et al., 2004).  As noted above, 
CHT-/- mice have reduced stores of ACh and exhibit perinatal lethality, displaying 
cyanosis possibly due to respiratory failure, thus limiting further phenotype 
characterization (Ferguson et al., 2004).  Thus, most of the studies examining the role of 
genetic loss of CHT have been conducted in CHT+/- mice (Table 3) (Bazalakova et al., 
2007).  Studies conducted in CHT+/- mice show reduced CNS tissue levels of ACh in 
addition to reductions in M2AChRs (Bazalakova et al., 2007).  The reduction in CNS 
M2AChRs likely represents an attempt by cholinergic neurons to attenuate these 
autoinhibitory receptors to improve cholinergic tone.  In the heart, reduction of M2AChRs  
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would diminish the cholinergic tone within the heart, thus leading to unopposed 
sympathetic tone resulting in tachycardia and increased cardiac output.   
Murine Models of Cholinergic Dysfunction in Behavioral Disorders 
 Cholinergic neurotransmission plays a significant role in mediating diverse and 
complex behavioral and neurologic functions within CNS and has been implicated in the 
cognitive impairments seen in schizophrenia and Alzheimer’s disease, and to play a role  
in the pathology of other psychiatric disorders such as major depressive disorder and 
anxiety disorders (Coyle et al., 1983; File et al., 2000; Tandon, 1999; Vakalopoulos, 
2007).  Pharmacologic strategies to improve cognitive impairments in both schizophrenia 
and Alzheimer’s disease have focused on increasing cholinergic neurotransmission 
(Friedman, 2004; Giacobini, 2000).  Additionally, agents working to improve the 
attentional deficits in ADHD have also been shown to improve ACh transmission 
(Tzavara et al., 2006).   
 Utilizing various genetic approaches, numerous transgenic murine models with 
either overexpression or knockout of components regulating cholinergic transmission 
have been created to evaluate the impact on behavior and neurologic function.  The 
coupling of changes in CHT-mediated HACU to increased turnover or release of ACh, in  
response to increased cholinergic demand, supports a critical role for CHT in 
cholinergically mediated behaviors (e.g.:  attention, learning, memory) (Arnold et al., 
2002).  Additionally, the cellular localization of CHT to both an intracellular vesicular 
and plasma membrane pools permits the mobilization of CHT to meet increased demands 
for cholinergically mediated behaviors (Ferguson et al., 2003).   And this may reveal 
itself under “challenge” such as sustained attention tasks.  
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 Several genetically modified mouse models examining the impact of alterations in 
the ACh synthesis machinery have been examined behaviorally.  Cholinergic signaling is 
terminated by the enzymatic hydrolysis of ACh by the enzyme AChE.   Loss of AChE 
may produce enhanced ACh signaling which may lead to a hypercholinergic state 
possibly resulting in death.  However, AChE-/- mice survive to adulthood, although they 
exhibit gastrointestinal difficulties and have shortened lifespans due to fatal seizures 
(Duysen et al., 2002; Xie et al., 2000).  These mice also demonstrate resistance to 
pilocarpine-induced seizures during activation of M1AChRs and resistance to 
oxotremorine-induced hypothermia and tremor compared to wild-type mice (Li et al., 
2003).  Although butyrylcholinesterase in AChE-/- mice was unchanged, [3H]quinuclinyl 
benzilate ([3H]-QNB) binding studies and immunoblotting for specific muscarinic AChR 
receptor subtypes demonstrated a 50 to 80% reduced expression of M1, M2 and M4 
receptors in cortex and hippocampal homogenates (Li et al., 2003; Volpicelli-Daley et al., 
2003). 
 Interestingly, in addition to changes in post-synaptic muscarinic AChRs, 
immunoblotting for CHT reveals a 60% increase in CHT expression in striatal 
homogenates, without compensatory changes in ChAT activity or VAChT expression 
(Volpicelli-Daley et al., 2003).  It has been hypothesized that the increase in CHT 
expression in AChE-/- mice may represent a compensatory change in the presynaptic 
neuron to recapture the choline-substrate in a cholinergic system that is lacking of ACh 
hydrolysis (Bazalakova and Blakely, 2006).   
The observed behavioral phenotypes in AChE-/- mice compliment behavioral 
findings in CHT+/- mice, even though CHT+/- have a 50% reduction in CHT protein 
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compared to wildtype mice.  CHT+/- mice exhibit a hyposensitivity to scopolamine 
challenge and are hyperresponsive to oxotremorine-induced seizures (Bazalakova et al., 
2007).  In addition, CHT+/- mice while exhibiting normal grooming and rearing 
behaviors, show significant exercise deficits on treadmill studies examining speed and 
endurance.  These results point to both presynaptic and postsynaptic mechanisms that 
work synergistically to maintain extracellular ACh levels and regulate cholinergic 
signaling. 
In contrast to AChE-/- mice, AChE transgenic (AChE-Tg) mice expressing 
human AChE show elevated AChE catalytic activity in synaptosomes from hippocampus, 
cortex and striatum, however the extracellular ACh concentration was similar between 
genotypes (Erb et al., 2001).  Synaptosomal homogenates show similar increases in CHT-
mediated HACU in the hippocampus, cortex and striatum of AChE-Tg mice (Erb et al., 
2001).  Similar to AChE-/- mice, AChE-Tg are resistant to muscarinic (oxotremorine)-
induced hypothermia, but exhibit normal responses to scopolamine (Beeri et al., 1995).  
AChE-Tg mice also display normal motor behavior to familiar environments, but 
increased motor activity to novel environments and increased anxiety-related behaviors in 
elevated plus-maze tests, findings that are in contrast to those of CHT+/- mice 
(Bazalakova et al., 2007; Erb et al., 2001).  These results show the compensatory increase 
of CHT-mediated HACU in the presence of a hypocholinergic state due to increased ACh 
hydrolysis in order to maintain cholinergic tone. 
Other changes in CHT regulation have been shown in other models of cholinergic 
deficits in ChAT+/- and in the α3 nicotinic receptor knockout (α3-/-) mice showing CHT 
upregulation and downregulation respectively (Bazalakova et al., 2007; Krishnaswamy 
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and Cooper, 2009).  The dynamic changes to CHT regulation due to changes in either 
pre- or post-synaptic cholinergic signaling mechanisms led to the characterization of 
CHT+/- mice.  CHT knockout (CHT-/-) display a post-natal lethality phenotype and limit 
useful behavioral or physiologic characterization, however CHT heterozygous (CHT+/-) 
mice develop normally and exhibit normal lifespans compared to their wildtype 
littermates (Bazalakova et al., 2007; Ferguson et al., 2004).  Initial behavioral 
characterization of CHT+/- mice showed similar performance to a variety of behavioral 
tasks including sensory-motor, motor coordination, overall locomotor activity, anxiety 
and spatial learning and memory tests (Bazalakova and Blakely, 2006; Bazalakova et al., 
2007) (Table 3).  These results led to the examination of behaviors, that require sustained 
cholinergic transmission with the hypothesis that CHT+/- mice would be unable to 
sustain releasable pools of ACh due to diminished capture of choline substrate.  During 
physical challenge with treadmill, CHT+/- mice were unable to reach high speeds as 
those attained by CHT+/+ mice and also showed deficits in endurance (Bazalakova et al., 
2007).  CHT+/- mice also showed hyposensitivity to scopolamine-induced locomotion, 
reflected by a reduction in M2AChRs in the striatum and cortex (Bazalakova et al., 2007).  
Although CHT+/- mice have 50% reduction in CHT protein and exhibit significantly 
reduced M2AChR compared to wildtypes, ChAT and AChE activity was similar between 
both genotypes.  These studies demonstrate that CHT heterozygosity results in adequate 
baseline stores of ACh capable of maintaining normal behavioral phenotypes, but that 
during sustained periods of increased cholinergic tone, CHT+/- mice are unable to 
maintain the pool of ACh and exhibit cholinergically-dependent phenotypes.  Further 
studies in CHT+/- mice performing attentional or cognitive tasks dependent upon 
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sustained cholinergic tone are required to define the behavioral impact and may provide 
insights of the role of CHT in human cognitive disorders (Sarter and Parikh, 2005). 
 
 
 49
Significance  
 
ACh was one of the first neurotransmitters discovered and plays a key role in 
modulating responses in both the central and peripheral nervous systems  (Burnstock, 
1979; Loewi, 1921).  Within the CNS, ACh modulates complex behavioral and motor 
functions, although in the periphery, ACh modulates respiration, gastrointestinal motility 
and autonomic nervous system functions (Burnstock, 1979; Kasa, 1986).  The choline 
transporter (CHT) serves as the rate-limiting step for the synthesis of ACh, and selective 
blockade of CHT by HC-3 reduces HACU and subsequent ACh synthesis and release 
(Apparsundaram et al., 2000; Maire and Wurtman, 1985).  Studies conducted by our lab 
shows that CHT-mediated HACU is regulated by neuronal activity and that genetic 
disruptions of CHT produce phenotypic consequences in vivo (Ferguson et al., 2004; 
Simon et al., 1976).   
The expirements conducted compliment previous studies conducted in the 
CHT+/- mice that focused primarily on CNS-mediated behaviors and extended them into 
the periphery examining the impact of CHT plasticity within the autonomic nervous 
system on the regulation of cardiac function.  These studies provide an ability to examine 
cardiovascular dynamics and function in the intact organism and provide critical insights 
in the impact of cholinergic disruptions on cardiovascular health. 
Additionally, the characterization of the CHT+/- mice may provide insight into a 
range of psychiatric disorders including cognitive disorders (ie. ADHD, Alzheimer’s) 
(Potter et al., 2006; Tzavara et al., 2006), schizophrenia (Tandon, 1999) and Parkinsons’s 
disease (Calabresi et al., 2006).  Similarly these mice may also be useful in characterizing 
neurologic disorders such as multiple sclerosis (Nizri et al., 2007) and the non-neuronal 
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impacts of cholinergic neurotransmission on the immune system (Kawashima and Fujii, 
2003a).  A formal understanding of the regulators of cholinergic function can provide 
extremely useful insights into a wide range of physiologic functions and pathology. 
 
Thesis Objectives 
 
Our lab developed CHT-/- and CHT+/- mice, affording the opportunity to 
examine CHT contributions to physiology.  The experiments conducted here examine 
CHT+/- and CHT+/+ animals utilizing biochemical, pharmacological, and surgical 
approaches to directly test the central hypothesis: CHT is essential for ACh synthesis 
and release in response to sustained demands on cholinergic signaling, and in turn 
supports parasympathetic (vagal) regulation of the heart and CNS functions 
including cognition and behavior.  Three specific aims were pursued to test the central 
hypothesis: 
 
Specific Aim 1. Determine the impact of genetic loss of CHT on cardiac HACU, 
CHT distribution, ACh levels and ACh/NE receptor expression and sensitivity. 
Hypothesis: As the rate-limiting step of ACh synthesis, CHT is essential for 
cholinergically-supported parasympathetic (vagal) tone within the heart. To test this 
hypothesis, I evaluated ACh/choline and NE/MHPG levels in cardiac tissues and used 
biochemical approaches to determine CHT activities, expression and muscarinic and 
adrenergic receptor levels in mouse heart. 
 
Specific Aim 2. Characterize the in vivo functional consequence and physiologic 
impact of genetic variation of CHT in mouse heart. Hypothesis: Reductions in the 
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intracellular pool of CHT, the rate limiting step in the biosynthesis of ACh, will alter 
parasympathetic (vagal) tone of the heart, resulting in an inability to produce lower 
resting heart rates.  To test this hypothesis, I surgically implanted telemetry devices to 
record HR and BP in conscious mice.  To determine the impact on cardiac function, I 
used echocardiography and histology.  I also performed exercise trials, baroreceptor 
reflex challenge and vagal nerve stimulation strategies to measure the impact of CHT loss 
on vagally driven bradycardic responses. 
 
Specific Aim 3. Determine the physiologic impact of known genetic variants within 
the human CHT gene in subjects with psychiatric and cardiovascular disorders. 
Hypothesis: Recently two variants within the choline transporter have been identified.  
One variant (Ile89Val) demonstrates a 50% reduction in Vmax.  Subjects carrying variants 
which affect CHT function may display symptom phenotypes associated with reduced 
cholinergic tone.  To test this hypothesis, I utilized the allelic-discrimination Taqman® 
genotyping assay to determine associations of the Ile89Val (rs1013940) and the 3’SNP 
(rs333999) variants in healthy controls and subjects diagnosed with various 
cardiovascular and psychiatric disorders.   
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CHAPTER II 
 
CARDIOVASCULAR EFFECTS OF CHT HETEROZYGOSITY – MOLECULAR 
ALTERATIONS AND INITIAL PHENOTYPIC FINDINGS 
 
 
Introduction 
 
 
 Acetylcholine (ACh) serves as an important neurotransmitter in the autonomic 
nervous system (ANS) serving as the sole neurotransmitter at the pre-ganglionic sites for 
both branches of the ANS, the sympathetic (SNS) and parasympathetic (PNS) nervous 
system activating nicotinic acetylcholine receptors (nAChRs) on the post-ganglionic 
neuron (Lefkowitz, 1996).   Additionally, the parasympathetic nervous system uses ACh 
at the post-ganglionic site acting on multiple subtypes of muscarinic acetylcholine 
receptors (mAChRs) regulating such diverse functions such as heart rate, respiration, 
gastrointestinal motility and secretions and urinary functions (Caulfield, 1993; Lefkowitz, 
1996).  Within the heart, cholinergic terminals from the vagus nerve synapse directly 
onto nAChRs containing intrinsic cardiac ganglia and cause post-ganglionic ACh release, 
resulting in activation of mAChRs within the sinoatrial (SA) and atrioventricular (AV) 
nodal regions of the myocardium (Caulfield, 1993; Hancock et al., 1987; Szabo and 
Otero, 1989).  Muscarinic antagonists such as atropine and scopolamine produce 
tachycardia by permitting sympathetic nervous system predominance at the SA and AV 
nodes, while muscarinic agonists such as bethanechol result in a bradycardic effect 
(Dhein et al., 2001; Loffelholz and Pappano, 1985). 
 The predominant mAChR in the mammalian heart is the muscarinic-2 subtype 
(M2AChR), which exhibits regional differences with the majority of mAChRs being 
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localized to the atria and nodal tissue versus the ventricular myocardium (Brodde et al., 
2001; Peralta et al., 1987).  However recent evidence has suggested the presence of M1- 
and M3AChR receptor subtypes have been identified in ventricular cardiomyocytes, with 
M1AChRs having been shown to enhance ICa currents and M1AChRs demonstrating 
effects on IKM3 currents, producing both ionotropic and chronotropic effects on the 
myocardium (Dhein et al., 2001).   
 Although additional muscarinic ACh-receptor subtypes have been identified 
within cardiomyocytes, the M2AChR serves as the predominant pre- and post-junctional 
muscarinic receptor subtype regulating the chrontopic effects of parasympathetic tone 
(Peralta et al., 1987).  Several animal studies have shown the primary contribution of 
M2AChRs in regulating the bradycardic effects of HR regulation.  In atria from M2AChR 
receptor knockout mice, stimulation with the M2AChR agonist carbachol, failed to illicit 
a bradycardic effect compared to wildtype mice (Gomeza et al., 1999).  Walker et al. 
investigating the role of cardiac role G-protein receptor kinase (GRK), found that GRK3 
knockout mice demonstrated similar carbachol-induced bradycardia to wildtype mice, 
however the baroreceptor reflex and HR recovery was significantly enhanced in these 
mice (Walker et al., 1999).   
 It is well known that HRV diminishes with age and that this reduction in overall 
HRV is due to the reduction in the HF component mediated by the parasympathetic 
nervous system (Pieper, 1995; Stein and Kleiger, 1999).  Studies examining the 
molecular mechanisms to this reduction in cholinergic tone have focused predominantly 
on the M2AChR and its signaling mechanisms.  In human studies, carbachol-induced 
inhibition of ACh release (as mediated by M2AChR autoreceptors) decreases with age 
 54
(Oberhauser et al., 2001).  Similarly, several studies have demonstrated an age-dependent 
association in the decrease in M2AChR densities in heart atrium (Brodde et al., 1998; 
Poller et al., 1997).  Conversely, in chronic heart failure, there is a substantial increase in 
the activity of Gi-protein activity and possible enhancement of M2AChR density possibly 
contributing to a salvaging mechanism by the parasympathetic nervous system to prevent 
further damage in the failing heart (Brodde and Leineweber, 2004; LaCroix et al., 2008).  
Additionally, the enzyme responsible for ACh degradation AChE, was found to be 
reduced in patients with HF (Dunlap et al., 2003).  These data support the importance of 
cholinergic signaling mechanisms in regulation of cardiovascular function. 
 Few studies have examined the role of HACU in the heart.  Previous animal 
studies have identified a HC-3 sensitive process that limits vagal ACh production and 
that the administration of HC-3 demonstrated failure of vagal control of heart atrium 
(Lewartowski and Bielecki, 1963; Vincenzi and West, 1966).  Lindmar, et al., 
demonstrated that electrical stimulation of chick heart explants led to a delayed increase 
in choline uptake (Lindmar et al., 1980).  Similarly, Na+-dependent, high-affinity, HC-3 
sensitive [3H]choline uptake was identified in isolated rat atrium, whereby chronic 
depolarization of the isolated atrium led to a compensatory upregulation of ACh 
synthesis, however whether this increase in ACh synthesis was coupled to an increase in 
CHT was not elucidated (Wetzel and Brown, 1983). 
 Since CHT-mediated HACU is believed to serve as the rate limiting step for the 
biosynthesis of ACh by providing critical precursor support, especially during high rates 
of cholinergic signaling, it is predicted that genetic perturbation of CHT function would 
limit cholinergic tone (Ferguson and Blakely, 2004; Simon and Kuhar, 1975).  In the 
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heart, both sympathetic and parasympathetic preganglionic neurons utilize ACh as their 
key neurotransmitter and disruption of CHT could affect both autonomic branches.  
However since the parasympathetic system also uses ACh as its postganglionic 
neurotransmitter, we predict that disruption of CHT would produce a larger impact on 
parasympathetic tone via vagal innervation to the heart, leaving sympathetic tone 
unabated and possibly resulting in cardiovascular dysfunction. 
 In the experiments described below, I sought to determine the impact of CHT 
heterozygosity on the parasympathetic (vagal) regulation of the heart at the molecular 
level and to identify potential cardiovascular phenotypes with associated with reduced 
vagal tone. 
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Methods 
Drugs 
(±)-metoprolol (+)-tartrate (M-5391) was obtained from Sigma Aldrich (St. Louis, 
MO, USA) and dissolved in sterile saline (0.9% NaCl).  Both drugs were injected 
intraperitoneally (i.p.) at a volume of 2 mg/kg.  Isoflurane, USP (Terrell™) was obtained 
from RxElite (Meridian, ID, USA) and used as a general anesthetic mixed at 1-3% with 
100% O2. 
 
Mice 
All animal procedures were approved by the Vanderbilt University Institutional 
Animal Care and Use Committee (Protocol # M/04/075).  Male mice (4-6 months old, 
young) were housed up to 5 per cage on a 12:12-h light/dark cycle (lights on at 0600h).  
Telemetry and cardiovascular experiments were performed during the light part of the 
cycle.  Food (Purina Rodent Chow #5001) and water were provided ad libitum.  All mice 
were back-crossed at least seven generations to the C57BL/6 background.  In all cases, 
CHT+/+ littermates were used as controls.  All cardiovascular experiments were 
performed in the laboratory of Dr. David Robertson of the Autonomic Dysfunction 
Center, Vanderbilt University. 
 
Analysis of choline transporter activity 
Crude atrial extracts from hearts of adult, male mice (n=4 mice/genotype) were 
prepared as previously described (Ferguson et al., 2003; Lindmar et al., 1980).  Assays of 
choline transport activity in heart atrial tissue were performed in triplicate for 5 min at 
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37°C in Krebs Ringer’s HEPES buffer (KRH:  130mM NaCl/3mM KCl/2.2 mM 
CaCl2/1.2 mM MgSO4/1.2 mM KH2PO4/10 mM glucose/10 mM HEPES, pH 7.4) with a 
final choline concentration of 100 nM (specific activity:  82 Ci/mmol, Amersham 
Pharmacia; 1 Ci = 37 GBq).  HC-3 at 10 μM was used to define CHT-mediated choline 
uptake.  Uptake assays were terminated by aspiration and washing onto 
polyethyleneimine-coated glass fiber filters with a Brandel (Gaithersburg, MD) cell 
harvester.  The low yield of tissue from the heart precluded analysis of saturation kinetics 
in these samples. 
 
Immunoblot analysis of CHT and mAChR expression 
Freshly dissected heart atrial tissue (n=4 mice/genotype) were first homogenized 
in 0.32M sucrose+HEPES buffer, then vortexed at 3650 x g at 4°C for 20 min.  The pellet 
was solubilized in 200 μl for 24 hours at 4°C in lysis buffer (1.0% Triton, 0.1% SDS, 50 
mM Tris pH=7.4, 100 mM NaCl and protease inhibitors).  Insoluble material was 
removed by centrifugation at 15,000xg.  Protein concentration was measured and 
normalized using the Bradford method, and samples loaded onto SDS-PAGE 1X 
Laemmali buffer (1% SDS, Tris 31.25 mM, pH 6.8, 5% glycerol, 200 mM 2-
mercaptoethanol).  Samples were then removed and centrifuged at 13,000 rpm at 4°C for 
20 min to remove cellular debris.  Samples were then normalized for protein 
concentration using the Bradford method and resolved by standard SDS-PAGE, and 
transferred electrophoretically to polyvinylidene diflouride (PVDF) membranes 
(Amersham Biosciences, Arlington Heights, IL) followed standard procedures (Ferguson 
et al., 2003).  Analysis of CHT, GAPDH and the M2AChR proteins from a single PVDF 
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membrane was performed after stripping of blots between incubations with 2% SDS, 
Tris-HCl 62.5 mM, pH=8, and 2-mercaptoethanol 100 mM at 55°C for 20 min.  After 
washing with PBS-T, blots were then blocked in 5% milk PBS-T before analysis with the 
next antibody. 
 
ACh and choline levels 
ACh levels in heart tissue were quantified by high-performance liquid 
chromatography using electrochemical detection (CHT+/+, n=11; CHT+/-, n=10) 
(Vanderbilt Neurochemistry Core Resource) as previously described (Damsma et al., 
1985).  Briefly, animals were decapitated and microwaved for 5 seconds to inactivate 
AChE degradation of ACh (Bertrand et al., 1994).  Hearts were then quickly removed 
and placed onto dry ice.  Heart samples were then homogenized in acetonitrile, and lipids 
removed using heptane and vacuum drying. 
 
Catecholamine levels 
Catecholamines (NE, Epi and metabolites) were measured in urine using spot 
collection from conscious adult male mice.  Resting mice were immediately removed 
from their home cages and urine collected in microtubes.  Urine was preserved in 6N HCl 
to prevent catechol breakdown and frozen at -80°C until analysis.  Catecholamines were 
measured after alumina extraction by high-performance liquid chromatography with 
electrochemical detection (Keller et al., 2006).    
 
Surgical placement of telemetric electrocardiogram transmitters 
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 All cardiovascular studies were performed in collaboration with the laboratory of 
David Robertson, MD at Vanderbilt University, with murine surgical assistance provided 
by Martin Appalsamy and experimental support provided by Nancy Keller.  
For long-term, ambulatory electrocardiogram (ECG) or blood pressure (BP) 
monitoring in conscious mice, telemetry devices (model TA10ETA-F20, ECG or TA10-
C20, BP; DataSciences International, St. Paul, MN) (Figure 12A) were implanted using 
sterile technique.  Mice were anesthetized with isoflurane 1% in 100% O2 at 1.5 L/min 
and body temperature maintained at 36-37°C with an isothermal pad (Braintree 
Scientific, Inc., Braintree, MA, USA).  Following antiseptic preparation, a midline 
incision was made subcutaneously along the back.  For ECG determination, an 
implantable, radio-frequency transmitter (TA10ETA-F20; 3.9g) was inserted into the 
subcutaneous pocket with leads directed caudally.  Using a trochar, the cathodal lead was 
placed over the scapula and anchored in place with permanent suture.  Another incision 
was made subcutaneously over the apex of the heart, through which using the trochar, the 
anodal lead was tunneled underneath the left front paw and sutured in place over the heart 
apex.  For BP determination, an implantable, transmitter (TA10-C20; 3.2g) was inserted 
into a subcutaneous pocket with the lead placed into the left carotid artery and advanced 
toward the bifurcation.  Skin was sutured and secured with veterinary adhesive 
(Nexaband, Veterinary Products Laboratories, Phoenix, AZ, USA).  Mice were allowed 
to recover for 5 days before use in experimental protocols. 
 
Electrocardiogram (ECG) and blood pressure (BP) recordings 
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After a 5-day post-operative recovery period, 24-hour continuous ECG recordings 
of HR were performed in telemeterized mice (CHT+/+, n=8; CHT+/-, n=8) for a period 
of 5 days.  Average HR and BP values were determined in CHT+/+ and CHT+/- mice 
during resting (light cycle) and awake (dark cycle) time periods.  ECG and BP signals 
were recorded in 1-second intervals using flatbed radio-frequency receivers (DSI 
PhysioTel, Receiver RPC-1, DataScience International, St Paul, MN) and a digital 
acquisition system (Dataquest A.R.T., Data Sciences International, St Paul, MN).  To 
determine the intrinsic HR, mice (n= 5/genotype) underwent challenge of metoprolol 
6mg/kg i.p. and methscopolamine 2mg/kg s.q. simultaneously.  Baseline HR was 
recorded 2 hours prior to administration of drug and for 2 hours post-administration of 
drugs.  Pharmacologic studies were performed in conscious, telemeterized mice 
(CHT+/+, n=6; CHT+/-, n=6) by giving metoprolol 2 mg/kg by i.p. injection. 
 
Statistical analysis 
 Data are expressed as mean ± S.E.M.  Statistical comparisons were with one-
tailed, unpaired Student’s t-test with 95% confidence limits comparing transgenic values 
to controls, or one-way repeated measures ANOVA followed by the Bonferroni 
procedure for multiple group comparisons as indicated in the figure legends.  The results 
were considered statistically significant if P<0.05.  The specific statistical tests used are 
noted in the text and legends with respect to individual test design. 
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Results 
 
CHT Hemizygosity Results in Elevated Heart Rate and Blood Pressure 
Realizing that deficits in CHT could affect both branches of the autonomic 
nervous system given that both preganglionic neurons utilize ACh, we hypothesized that 
since the parasympathetic branch utilizes ACh at both pre-and postganglionic neurons, 
that deficits in CHT+/- mice would be due to reductions in PNS tone.  Therefore, we 
predicted that CHT+/- mice would exhibit reduced vagal regulation of HR.  Previous 
examination of subcutaneous heart rate recordings in anesthetized neonatal CHT+/- and 
CHT-/- mice demonstrated two distinct phenotypes (Figure 12B):  1.  CHT+/- mice 
exhibited higher heart rates (220±22 bpm, n=4) when compared to WT neonatal mice.  2.  
CHT-/- mice exhibited significantly lower HR (80±15 bpm, n=14) compared to WT mice 
(Mihaela Bazalakova, unpublished data).   The finding of tachycardia in CHT+/- was 
expected given our original hypothesis that loss of CHT could produce a reduction in 
vagal tone, however the finding of bradycardia in CHT-/- mice was unexpected.  
However, since CHT-/- mice appear anoxic at birth, many other factors impacting overall 
viability such as the reduction in respirations may impact HR (Ferguson et al., 2004). 
In order to avoid complications of anoxia and neonatal lethality in CHT-/- mice, 
we focused on CHT+/- mice for the rest of our experiments.  Earlier HR recordings in 
CHT+/- mice although showing elevated HRs compared to WT, were done under 
isoflurane anesthesia.  While isoflurane is reported to have the least cardiogenic effects 
(Rottman et al., 2003), our early experiments showed that isoflurane produced a  
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Figure 12. Initial HR recordings in CHT+/- and CHT-/- mice. (A) DSI
telemetric device for ECG recordings in mice. (B) ECG recordings were
obtained in unaesthetized newborns, using a lead II position Gould
Amplifier and WinDaq Acquisition System. Mean heart rate values were
276±9 bpm in the CHT+/- (n=6), 220±22 bpm in the CHT+/+ (n=4), and
80±15 bpm in the CHT-/- (n=12) * P<0 05 two-tailed Student’s t-test. ,
(values ±SEM). (Data courtesy of Mihaela Bazalakova, MD, PhD)
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reduction in overall HR in our CHT+/- mice (Brett English; unpublished data).  In order 
to characterize more accurate heart rate and blood pressure measurements, we implanted 
ECG (TA-10) and blood pressure (PA-20) telemetry devices into CHT+/+ and CHT+/- 
mice allowing us to characterize HR, mean, systolic and diastolic blood pressures in 
conscious, freely-moving animals.   
Recording of resting and activity-dependent heart rates were measured in 
conscious, freely-moving, chronically telemeterized mice over a 24 hour period for 5 
days.  CHT+/- mice exhibited significantly higher mean resting (Day) HR (CHT+/+, 
538.8±8.2; CHT+/-, 567±8.1; P=0.017) compared to CHT+/+ mice (Table 4 and Figure 
13A).  There were no significant genotype differences exhibited in HR during the active 
period (Nighttime) in either genotypes (Figure 13A).  As a measure of the ability of the 
PNS to reduce the HR to a resting level, we measured the change in HR over a 2-hour 
period from the maximal HR achieved during increased motor activity, to its return 
during rest.  Over the 2 hour monitoring period, both CHT+/+ and CHT+/- mice reduced 
HR by similar levels, however at the end of the 2 hour period, CHT+/- mice continued to 
have significantly elevated HR compared to CHT+/+ mice.   
CHT+/- mice also exhibited significantly higher mean, resting (Day) blood 
pressures (CHT+/+, 98.20±1.2; CHT+/-, 104.9±2.1 mmHg; P<0.05) compared to 
CHT+/+ mice (Figure 13B).   In CHT+/- mice, the elevation in mean resting BP was 
driven by significant increases in systolic BP between the two genotypes (Figure 13C).  
As with HR, activity-associated BP was similar between genotypes (data not shown).  
Evaluation of sympathetic tone using metoprolol (2mg/kg i.p.) showed that CHT+/- mice 
displayed significantly blunted response (CHT+/+, -166.0±36.5; CHT+/-, -66.8±22.23  
A B
*
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*
Fig. 13. CHT+/- mice show elevated HR and BP, and display reduced
sensitivity to β-adrenergic receptor blockade (A) CHT+/- mice display.
significantly elevated resting (day) HRs vs. CHT+/+ mice (*P<0.01),
while activity (night) HRs are similar. (B) Similarly, CHT+/- mice exhibit
elevated resting mean BP (mBP) vs. CHT+/+ mice (*P<0.05). (C)
Increase in resting mBP is due to increased systolic BP (SBP) in CHT+/-
mice (*P<0.03). (D) Reduced sensitivity to metoprolol 2 mg/kg i.p. is
exhibited in CHT+/- mice vs. CHT+/+ *(P<0.02). (CHT+/+, n=7-8;
CHT+/-, n=7-8). Significance as determined by one-tailed, unpaired
Student’s t-test, Values represent ±SEM.
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mmHg, P<0.05) to β-adrenergic blockade (change in HR from baseline) compared to 
CHT+/+ mice (Figure 13D).    
 
Loss of Cardiac CHT Results in Reduced Tissue Levels of ACh and Choline 
Reductions in CHT-mediated choline uptake and expression of CHT could 
possibly result in decreases in availability of ACh within intracardiac ganglia. Previous 
studies had shown that CHT+/- mice exhibited a 50% reduction in the expression of CHT 
and subsequent reduction in tissue levels of ACh within mouse brain.   Similar to 
observations in CHT+/- mouse brain, CHT+/- mice whole heart tissue levels of ACh 
were significantly lower (CHT+/+, 6.2±0.8; CHT+/-, 3.7±0.7 nmol/g wet tissue; 
P=0.028) compared to CHT+/+ mice (Figure 14A).  Unlike that found in CHT+/- mouse 
brain tissue levels of choline were reduced to CHT+/+ mice (CHT+/+, 305.2±41.6; 
CHT+/-, 225.3±23.0 nmol/g wet tissue; P=0.05) (Figure 14B).  
 
CHT+/- Mice Exhibit Increased Cardiac Tissue NE and MHPG Levels 
Reduced parasympathetic tone has been shown to contribute to autonomic 
instability leading to an increased sympathetic tone (Palatini and Julius, 2004).  To test 
this hypothesis, we collected urine from conscious, mice (CHT+/+, n=9; CHT+/-, n=9) 
during their resting period and measured catecholamine levels.  CHT+/- mice displayed 
elevated urinary levels of norepinephrine (NE) (CHT+/+, 125±10.3; CHT+/-, 195.8±34.5 
pg/μl; P=0.05) and epinephrine (EPI) (CHT+/+, 3.9±0.3; CHT+/- 6.8±1.3 pg/μl; P=0.05) 
compared to CHT+/+ mice (Figure 14C-D). 
 
Fig. 14. Cardiac tissue levels of ACh and choline are reduced, and
NE/Epi are elevated in CHT+/- mice. (A) Tissue ACh levels measured by
high-performance liquid chromatography are significantly lower in whole
hearts of CHT+/- mice. (B) Tissue levels of choline are lower in CHT+/-
vs CHT+/+ mice. (C) Urinary levels of NE and Epi (D) are elevated in
CHT+/- mice compared to CHT+/+. (CHT+/+, n=9; CHT+/-, n=9).
Significance as determined by one-tailed, unpaired Student’s t-test,
* 0 0 9/ l SP< . 5, n= genotype. Va ues represent ± .E.M.
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CHT+/- Mice Exhibit Altered Cardiac CHT-mediated HACU, CHT and M2AChR 
Expression in Atrial Tissue 
To test whether altered CHT expression or function contributed to the reduced 
cardiac tissue levels of ACh, we measured CHT-mediated HACU and CHT expression in 
cardiac atrial tissue preparations.  Isolated atria from CHT+/- mice displayed reduced 
HC-3 sensitive [3H]choline transport rates compared to CHT+/+ atria (Figure 15A).  
These reductions in HACU were supported by a reduction in CHT protein expression 
(Figure 15B and C) in CHT+/- mice compared to CHT+/+ mice. Quantitation of post-
synaptic M2AChRs in the same samples did not reveal significant differences in receptor 
expression between genotypes (Figure 15D).   
 
Discussion 
Previous studies have identified the HC-3-sensitive, Na+/Cl--dependent, high-
affinity choline uptake mechanism as the rate-limiting step for ACh biosynthesis (Simon 
et al., 1976).  Several murine models with genetically-modified cholinergic deficits have 
provided evidence for the critical role that CHT plays in modulating cholinergic 
neurotransmission.   For example, in AChE-/- mice, expression of CHT is increased by 
60%, which may reflect an attempt by the presynaptic terminal to increase capture of the 
choline substrate due to its lack of production by ACh hydrolysis (Volpicelli-Daley et al., 
2003).  Previous studies conducted by our lab have shown that availability of CHT is 
necessary for the production of ACh and that CHT-/- mice exhibit a perinatal lethality 
phenotype (Ferguson et al., 2004).  In contrast, CHT+/- (hemizygous) mice appear 
normal compared to CHT+/+ mice, displaying normal lifespans, reproduction capability  
Fig. 15. CHT+/- mice display reduced cardiac CHT-mediated HACU
and CHT expression. (A) In cardiac atrial preparations, CHT+/- show
diminished HC-3 sensitive, [3H]choline uptake compared to CHT+/+ atria.
(B) CHT expression is significantly reduced in CHT+/- atria compared to
CHT+/+, quantitated in (C). (D) Expression of cardiac M2AChRs is
similar between genotypes. CHT protein quantitation is shown below.
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Significance as determined by one-tailed, unpaired Student’s t-test,
*P<0.05, n=4/genotype. Values represent ± S.E.M.
.
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and sensory-motor behaviors (Bazalakova et al., 2007).  However, while CHT+/- mice 
appear normal when compared to CHT+/+ mice, detailed examination of specific 
behaviors, which depend largely upon sustained cholinergic neurotransmission, CHT+/- 
mice show significant phenotypes consistent with attenuated cholinergic tone.  For 
example, CHT+/- mice exhibit deficits in sustained treadmill motor tasks and 
pharmacologically-mediated hyperlocomotive behaviors (Bazalakova and Blakely, 2006; 
Bazalakova et al., 2007).  Additional studies conducted in rats subjected to cognitive 
vigilance tasks, a cholinergically-mediated attention-performance task, exhibited 
increases in CHT-mediated HACU compared to controls (Apparsundaram et al., 2005).  
These results provided evidence that cholinergically-mediated behaviors requiring 
sustained ACh transmission depended upon availability of CHT and that disruptions of 
CHT-mediated HACU may possibly produce phenotypes consistent with attenuated 
cholinergic tone. 
In the periphery, the parasympathetic nervous system plays a critical role in 
regulating many of the vegetative physiologic processes (Lefkowitz, 1996).  Activation 
of parasympathetic inputs via vagal efferent projections to the heart results in bradycardia 
and contributes to resting HR (Fox et al., 2007; Lefkowitz, 1996).  Genetically-modified 
mice with deficits in ACh biosynthesis machinery such as ChAT or AChE, exhibiting 
hypocholinergic states, have not been studied with respect to their cardiovascular 
phenotypes.  In contrast, murine models featuring genetic deficits in postsynaptic 
cholinergic signaling mechanisms have been examined for their impact on cardiovascular 
regulation.  For example, studies conducted in M2AChR knockout mice show loss of 
vagally mediated bradycardia (Fisher et al., 2004).  Additionally thought M2AChR KO 
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mice display similar resting HRs compared to wildtype mice, chronic stimulation with 
isoproterenol in M2AChR KO mice results in significantly impaired ventricular function 
(LaCroix et al., 2008).  Given the results of increased CHT-mediated HACU in 
maintaining cholinergically-mediated behaviors, and that CHT+/- mice exhibited deficits 
in motor function tests, we hypothesized that CHT+/- may display altered vagal 
regulation of the cardiovasculature.   
Unlike the diffuse cholinergic innervation within the CNS, cholinergic 
innervation within the heart is limited to the intrinsic cardiac ganglia (ICG) and contain 
the postganglionic parasympathetic neurons which provide cholinergic innervation to the 
cardiac myocytes (Hoard et al., 2008).  These ganglia are localized within the atrial 
epicardium and receive cholinergic input from preganglionic vagal efferent neurons 
located in the medulla (Hoard et al., 2008; Parsons et al., 1987).    Expression of CHT has 
been demonstrated within guinea pig and adult mouse heart, but localized primarily to the 
atrial nodal tissue and the atrium, with little expression within the ventricles (Hoover et 
al., 2003; Mabe AM, 2006).   
Alterations in total ACh and choline levels have been observed in several human 
disorders and in transgenic murine models of Alzheimer’s Disease (Bales et al., 2006).  
Similarly, CHT+/- mice show significantly reduced tissue levels of ACh within the 
cortex, hippocampus and striatum (Bazalakova et al., 2007).  Additionally, CHT+/- mice 
show increased choline levels within the same brain regions and likely represent a 
compensatory attempt by additional choline uptake mechanisms to enrich choline supply 
for ACh synthesis (Bazalakova et al., 2007). Possible compensatory mechanisms could 
include upregulation of the low affinity, Na+-independent choline uptake which has been 
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identified in rodent astrocytes (Inazu et al., 2005).  Given these results and the expression 
patterns of CHT, we hypothesized that CHT+/- mice may have reduced tissue levels of 
ACh within cardiac atria.  CHT+/- mice exhibited significantly reduced tissue ACh 
levels, consistent with similar observations found within various regions within CHT+/- 
brain (Figure 14A).  However unlike that found in CNS, CHT+/- mouse heart had 
reduced tissue levels of choline compared to CHT+/+ mice (Figure 14B).  These 
observed differences may reflect the limited innervation of cholinergic neurons into the 
heart, whereas the changes within the CNS may represent compensatory attempts by non-
neuronal cells to increase tissue choline levels to help sustain ACh synthesis (Loffelholz 
and Pappano, 1985).  Similarly, the differences in tissue levels of choline in the mouse 
heart may also reflect limited expression of additional choline uptake mechanisms that 
can support ACh synthesis, since lower order mammals have been shown to rely more 
upon elevated sympathetic tone in cardiovascular regulation (Fisher et al., 2004; 
Wickman et al., 1998).  Lastly, the reduced ACh and choline levels may reflect changes 
in the redistribution of vesicular pools of ACh, where readily-releasable pools in CHT+/- 
mice are similar to CHT+/+, but that reserve pools are compromised (Birks and 
Macintosh, 1961).  Preliminary studies measuring [3H]ACh levels in brain slices after 
uptake show that CHT+/- mice have normal basal [3H]ACh levels which may reflect 
stability of readily releasable vesicular pools (D. Lund, M. Bazalakova; unpublished 
data).     
 In the context of reduced cardiac tissue levels of ACh in CHT+/- mice and the 
role of the vagal feedback mechanisms on sympathetic tone, we sought to determine the 
level of circulating catecholamines in CHT+/- mice.  In addition to the direct effects of 
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vagal signaling to the heart, activation of vagal efferents also results in a presynaptic 
blunting of sympathetic outflow, mediated by M2AChR receptors (Lefkowitz, 1996). 
Reduced parasympathetic tone has also been shown to contribute to autonomic instability 
leading to an increased sympathetic tone (Palatini and Julius, 2004).  We found that 
CHT+/- mice displayed elevated urinary levels of both NE and EPI compared to CHT+/+ 
mice (Figure 14C, D).  Elevation in CHT+/- urinary catecholamines could reflect 
changes in M2AChR expression, as activation of pre-synaptic cholinergic inputs to the 
medulla, blunts sympathetic outflow.  Functional compensation within the CNS of 
CHT+/- mice have been shown, with decreased expression of M2AChRs in the striatum 
and cortex (Bazalakova et al., 2007).  A downregulation of M2AChRs is consistent with 
compensatory changes in mAChR expression and function in AChE-/- mice, another 
model of cholinergic dysfunction (Volpicelli-Daley et al., 2003). 
    Deficits in cardiac CHT expression, cardiac tissue levels of ACh and elevated 
urinary catecholamines, pointed to reduced vagal regulation of the heart, thus we 
hypothesized that CHT+/- mice would exhibit a cardiac phenotype. To examine the 
impact of CHT loss on the cardiovasculature, we utilized implantable telemetry devices 
in freely moving mice.  Our data indicate that CHT+/- mice exhibit a basal resting 
tachycardia and increased afterload compared to CHT+/+ mice (Table 1).  Though the 
differences in resting HR and BP were statistically significant, the actual differences 
between both genotypes were not large.  This could be explained by compensated CHT 
kinetic activity between the genotypes in vivo, providing for near normal cholinergic 
tone.  As previously mentioned, vagal contributions to resting HR is lower in smaller 
mammals, thus the small differences in our CHT+/- mice may also reflect a lower 
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requirement of vagal contributions to resting HR in mice.  The contributions of 
diminished CHT reserve may therefore be more pronounced during increased phasic 
demands on vagal tone, such as baroreceptor-mediated bradycardia or heart rate recovery 
after exercise.  Similarly, since elevated resting HR has been shown to be a predictor of 
cardiovascular mortality, these small elevations may be more pathologic if experienced 
chronically (Fox et al., 2007; Palatini, 1999).    
Long-term elevation in HR and BP has been shown in both humans and animal 
models to result in heart failure (Brodde et al., 2001; Brum et al., 2002).  Though 
cholinergic of the vasculature is limited, CHT expression has been identified in rat and 
human arteries (Lips et al., 2002).  The role of the parasympathetic cholinergic nerves in 
vasodilation was first identified in the cerebral circulation (Busija and Heistad, 1981).  
Recent studies have shown that vagally-mediated vasodilation is modulated by M2AChRs 
and the nitric oxide (NO) interactions (Lepori et al., 2001; Sartori et al., 2005).   
Although the findings of elevated BP in CHT+/- mice (Figure 13B and C) may be 
reflective of reduced cholinergic activation of NO-mediated vasodilation, our findings of 
elevated systolic BP in the absence of elevated diastolic BP may be the result of 
increased CO due to increased sympathetic tone.      
 In conclusion, we have shown that CHT+/- have reduced CHT expression and 
HACU in intrinsic cardiac ganglia, representative of reduced vagal regulation of the 
heart.  CHT+/- mice exhibit small, but significant increased HR and BP, that while not 
producing overt pathology, may predispose these mice to future cardiovascular risk if 
these parameters are elevated chronically.  These finding in CHT+/- mice may have 
important clinical implications in human cardiovascular disorders as a hypomorphic 
 76
variant in the human CHT has been identified and found to have a minor allele frequency 
of 6% in a healthy population (Okuda et al., 2002).   
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CHAPTER III 
 
IMPACT OF CHT HEMIZYGOSITY ON AUTONOMIC REGULATION OF 
CARDIAC FUNCTION 
 
 
Introduction 
 
Healthy cardiovascular function is reliant upon a balanced and responsive 
collaboration between sympathetic and parasympathetic innervation of the heart 
controlling inotropic and chronotropic responses.  Elevated resting heart rate (HR) has 
been significantly associated with cardiovascular mortality in both healthy patients and in 
those with various cardiovascular disorders (Fox et al., 2007; Palatini, 1999).  The 
parasympathetic branch (PNS) of the autonomic nervous system projects to the heart via 
the vagal nerve efferents to produce bradycardia through the release of ACh.  ACh acts 
here on M2AChRs, whereas vasodilation of the peripheral arteries through nitric oxide 
(NO) signaling pathways (Lefkowitz, 1996; Lepori et al., 2001).  Disruptions in 
parasympathetic transmission may lead to sympathetic predominance resulting in 
elevated HR and BP, whereby long-term elevations in HR and BP have been shown in 
both human and animal models to produce heart failure (HF), myocardial infarction (MI) 
and sudden cardiac death (Brodde and Leineweber, 2004; Brum et al., 2002; Kannankeril 
and Goldberger, 2002).  Increases in sympathetic tone can lead to autonomic instability 
and effect normal physiologic functions such as heart rate variability (HRV), 
baroreceptor sensitivity (BRS), and heart rate recovery (HRR) after exercise, which have 
both been shown to be independent risk predictors for increased mortality associated with 
cardiovascular disease (Cole et al., 1999; La Rovere, 2001). 
 78
Across a diverse patient population, heart rate recovery (HRR) after exercise has 
been shown to be an independent predictor of mortality and a large, prospective, multi-
center study demonstrated that abnormal HRR after submaximal exercise predicted death 
(Cole et al., 2000; Smith et al., 2005).  Several studies have shown that elevated PNS 
activity protected against ventricular fibrillation and may be protective against cardiac 
sudden death (Kannankeril and Goldberger, 2002; Smith et al., 2005).  One potential 
mechanism is the direct effect of parasympathetic tone on cardiac electrophysiology, 
prolonging the sinus cycle length, AV conduction time and ventricular refractory period 
(Kannankeril and Goldberger, 2002).  In addition to direct parasympathetic effects, 
exercise itself has also been shown to improve resting HR and parasympathetic tone 
(Freeman et al., 2006). 
In addition to HRR, baroreceptor reflex sensitivity (BRS), a marker of cardiac 
vagal activity, was shown in a large prospective trial to be a strong independent predictor 
of mortality in patients with MI, with patients who exhibited a depressed BRS having an 
18% mortality rate (La Rovere, 2001).  The baroreceptors are stretch receptors located in 
the carotid sinuses and aortic arch, and detect acute changes in blood pressure.  Upon 
acute increases in BP, these mechanoreceptors trigger vagal efferents resulting in a 
decrease in HR and reduction in cardiac output (CO).  Experimentally, determination of 
the BRS index is performed by giving intravenous injections of a pressor agent, 
phenylephrine (PE), and a vasodilating agent, sodium nitroprusside (SNP) (Ma et al., 
2002).  The bradycardic effects elicited by the transient increase in SBP due to PE 
challenge have been shown to be primarily mediated by cholinergic projections of vagal 
efferents, activation of α2-adrenergic autoreceptors have also been shown to augment the 
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bradycardic effects (Tank et al., 2004).  These results were confirmed in mouse models 
where baroreceptor reflex is attenuated in α2-adrenergic receptor knockout mice during 
challenge with PI (Niederhoffer et al., 2004).  Nicotinic acetylcholine receptors 
(nAChRs) in autonomic ganglia have been shown to regulate autonomic functions 
affecting HR and BP.   Studies conducted in α7 nAChR unit knockout mice show 
impaired sympathetic responses to vasodilation, but a supersensitivity to direct acting 
adrenergic agonists (Franceschini et al., 2000).  Surprisingly, parasympathetic tone was 
normal in the α7 nAChR KO mice compared to controls (Franceschini et al., 2000).  
These results indicate that the α7 nAChRs in sympathetic ganglia participate in the 
maintenance of blood pressure during the autonomic reflex.   
 Our previous findings of a reduction in CHT expression, CHT-mediated 
HACU, elevated urinary catecholamines and the elevated HRs in CHT+/- mice pointed 
towards the hypothesis in CHT+/- mice exhibiting reduced parasympathetic tone in 
regulating HR.  However, our phenotypic studies were conducted in the basal resting 
state and dependent upon tonic vagal activity.  We therefore sought to determine the 
effects of CHT loss on regulating cardiovascular physiology dependent upon increased 
(phasic) vagal tone such as BRS and HRR.   
In the experiments described below, I sought to determine the impact of CHT 
heterozygosity on the parasympathetic (vagal) regulation of the baroreceptor reflex 
(BRS), recovery of HR after exercise (HRR).  Additionally I sought to determine the 
effects of direct acute and chronic vagal nerve stimulation (VNS) in eliciting a 
bradycardic response and the impact of a genetic loss of CHT in CHT+/- mice on their 
ability to sustain the bradycardia. 
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Methods 
 
Drugs 
l-Phenylephrine hydrochloride (P-6126) and sodium nitroprusside dihydrate (S-
0501) were obtained from Sigma Aldrich (St. Louis, MO, USA) and dissolved in sterile 
saline (0.9% NaCl).  Both drugs were injected intravenously at a volume of 10μl/kg.  
Isoflurane, USP (Terrell™) was obtained from RxElite (Meridian, ID, USA) and used as 
a general anesthetic mixed at 1-3% with 100% O2. 
 
Mice 
All animal procedures were approved by the Vanderbilt University Institutional 
Animal Care and Use Committee (Protocol # M/04/075).  Male mice (4-6 months old, 
young; 11-12 months old; aged) were housed up to 5 per cage on a 12:12-h light/dark 
cycle (lights on at 0600h).  Telemetry and cardiovascular experiments were performed 
during the light part of the cycle.  Food (Purina Rodent Chow #5001) and water were 
provided ad libitum.  All mice were back-crossed at least seven generations to the 
C57BL/6 background.  In all cases, CHT+/+ littermates were used as controls.  All 
cardiovascular experiments were performed in the laboratory of Dr. David Robertson of 
the Autonomic Dysfunction Center, Vanderbilt University. 
 
Surgical placement of telemetric blood pressure devices for acute studies 
For short-term, acute studies of baroreceptor sensitivity, mice were anesthetized 
and temperature maintained as described in Chapter II (Methods).  Following antiseptic 
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preparation, the left carotid artery was isolated, distal occlusion by suture of vessel was 
placed 8-10 mm below the bifurcation to occlude blood flow, and the lumen cut to allow 
insertion of the transmitter catheter (model TA10-C20; DataSciences International, St. 
Paul, MN, USA) to the point of bifurcation.  For intravenous administration of drugs, the 
right jugular vein was then isolated, distal occlusion of the vessel by suture, and lumen 
cut to allow insertion of the venous catheter (Micro-Renathane, model MRE-025 0.025 
O.D. x 0.12 I.D.; Braintree Scientific, Braintree, MA.).  During the baroreceptor studies, 
mice were kept on 0.65% isoflurane on 100% O2 at 1.5 L/min.  Mice were then 
sacrificed at the end of the study by intravenous urethane. 
 
Baroreceptor reflex sensitivity studies 
Determination of baroreceptor-mediated cardio-inhibitory response, mice 
(CHT+/+, n=8; CHT+/-, n=8) underwent a challenge with phenylephrine (PE) (5-30 
µg/kg) and Na+-nitroprusside (SNP) (5-30 µg/kg) given intravenously using a syringe 
pump (CMA 400 pump, CMA Microdialysis, Stockholm, Sweden) in a dose-response 
manner in anesthetized mice.  Baseline ECG and BP was recorded for 1.0 min prior to 
administration of drug and post-drug response was recorded for 3.0 min after 
administration.  The ratio of the maximal change in HR over the change of mean arterial 
blood pressure (MABP) was calculated and averaged at each dose in each animal.  
Baroreceptor sensitivity (BRS) was determined by the averaged ratio of HR change over 
MAPB change (ΔHR/ΔMABP) (Lin et al., 2007). 
 
Heart rate recovery/treadmill studies 
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Mice (CHT+/+, n=9; CHT+/-, n=8) chronically telemeterized with BP 
transducers, (as described above) were run on a two-lane motorized treadmill (Columbus 
Instruments, Columbus, OH, USA) equipped with an adjustable-speed belt (0-90 m/min) 
and an electric shock grid at one end.  On Day-1 (training-1) the mice were exposed to 
the treadmill for 10 min without shock.  Mice were then exposed to two timed runs (5 
min duration) at 5 and 10 m/min with 10-minute recovery periods between runs.  On 
Day-2 (training-2), mice were then exposed to the treadmill in the presence of shock (2 
mA, 4 min-1 frequency) activated by physical contact with the grid.  The mice were then 
run on the treadmill starting at 5m/min and gradually increased 2m/min every 2 minutes 
until exhaustion.  Exhaustion was defined as resting on the electric grid >15 sec/min or 
falling back onto the grid >15 times/min (Bazalakova et al., 2007).  On Day-3 (fixed 
speed/time), mice were run on the treadmill for 13m/min for 5 min.  HR and BP were 
collected in home cage 30 min prior to exercise challenge and during the 60 min recovery 
period after the 5 min treadmill run. 
 
Vagal nerve stimulation (VNS) studies 
Mice (CHT+/+, n=9; CHT+/-, n=9) were anesthetized as described above and a 
cervical midline incision was performed and right vagus nerve isolated from surrounding 
tissues.  The nerve was then placed on a pair of platinum hook electrodes (PT101 
(25mm), World Precision Instruments, Inc, Sarasota, FL, USA) and covered with silicone 
gel for insulation and immobilization (Tsutsumi et al., 2008). To determine cardiac 
sensitivity to VNS, two protocols were utilized.  In protocol-1 (frequency-response), the 
vagus nerve was stimulated with rectangular wave pulses of 1-ms duration, in 
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randomized frequencies 1-50Hz, 20 sec duration.  Baseline HR was recorded for 1 min 
prior to the stimulus and 5 min post-stimulus.  Mice were given 10 min recovery periods 
between stimulations.  In protocol-2 (saturation), the vagus nerve was stimulated at 20 Hz 
for 5 min continuously in order to determine the duration of bradycardia with constant 
vagal stimulation.   
 
Chronic exercise/swim studies 
CHT+/+ and CHT+/- mice (ages 4-7 mo) were randomly divided into 4 groups.  
The control group (CHT+/+, n=4, CHT+/-, n=4) did not perform any exercise.  The 
exercise group (CHT+/+, n=4; CHT+/- n=3) were trained two-times per day for 5 min 
duration for days 1 thru 6, and two-times per day for 10 min for days 7-10.  After 
successful training, the exercise group were subjected to the chronic swim/exercise 
protocol consisting of 10-minute swims, two-times per day for 30 days.  The chronic 
swim protocol established by Evangelista, et al. (Evangelista et al., 2003) consisted of a 
Plexiglas tank, 225 cm2, water depth of 15-20 cm, water temperature of 30-35°C.  To 
determine changes in cardiovascular function, 2-D targeted, M-mode echocardiography 
was performed at baseline and at the end of the chronic exercise period.  
Echocardiographically defined measurements of LV function were calculated as 
previously described (Rottman et al., 2003).   
 
2-D and M-mode echocardiography (Echo) 
Transthoracic echocardiography was performed using a system (Sonos 5500, 
Agilent, Andover, Mass.) with a 15-MHz high-frequency linear transducer at a frame rate 
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of 100 frames/sec in young (4-6 months old) (CHT+/+, n=8; CHT+/-, n=8) and aged (10-
12 months old) CHT+/+, n=9; CHT/, n=8).  All images were acquired at a depth setting 
of 20 mm.  Echocardiography was performed in conscious mice.  Before the study, mice 
were trained by holding mice by the nape of the neck, holding it in one hand in the prone 
position for at least 5 minutes.  During the procedure, mice were held in the position 
required for echocardiographic imaging.  The mouse chest was not shaved; ultrasound-
coupling gel heated to 34C was applied to the precordium.  Optimal parasternal long- and 
short-axis views were obtained by visualization of endo- and epicardial walls.  Two-
dimensional targeted, M-mode echocardiographic images were obtained to determine LV 
systolic (LVIDs) and diastolic (LVIDd) internal dimensions as previously described 
(Rottman et al., 2003; Syed et al., 2005).   These parameters allowed determination of LV 
fractional shortening (FS %) by the equation:  %FS=[(LVIDd-LVIDs)/LVIDd]x100%.  
Additional echocardiographic parameters were calculated using M-mode data as 
previously described (Collins, 2003; Syed et al., 2005). 
 
Histologic analysis 
Mice (CHT+/+, n=6; CHT+/-, n=6) were weighed and hearts dissected at 2 and 12 
months of age.  Dissected mouse hearts were rinsed and weighed in PBS.  Hearts were 
cut in cross-section just below the papillary muscle, and the top half fixed in formalin and 
embedded in paraffin.  Sections (5 μm) were prepared at 200 μm intervals and fixed with 
hematoxylin and eosin (H&E) for gross examination, Masson’s Trichrome (MT) for 
quantification of fibrosis, and Periodic Acid-Schiff, counterstained with hematoxylin 
(PAS-H) to determine cardiomyocyte size (Barrick et al., 2007). 
 85
Results 
 
 
CHT Deficiency Leads to Impaired Heart Rate Recovery after Exercise. 
 
Blood pressure tracings during exercise were of good quality for calculation of 
HR and mean BP (mBP).  As expected, resting baseline HRs in CHT+/- mice were 
significantly higher compared to CHT+/+ mice (P<0.001; Figure 16A).  During the 5-
min treadmill exercise run, both CHT+/+ and CHT+/- mice exhibited similar onset and 
maximal HR increases (Figure 16A).  With cessation of exercise, both CHT+/+ and 
CHT+/- mice achieved a resting heart rate equivalent to their pre-exercise levels, though 
CHT +/- mice required 27% longer to achieve full recovery  (CHT+/+, 24±3.4 min; 
CHT+/-, 33±2.4 min, P<0.05).  When changes in HR from peak values were calculated 
during the recovery period (Figure 16B), CHT+/- mice displayed overall deficits in HR 
recovery (P<0.05, CHT+/+, n=9; CHT+/-, n=8; Figure 16B). Moreover, three periods of 
differential HR adjustment became evident. Although CHT +/- animals generated 
consistently smaller reductions in HR during the first ~10 minutes of recovery, these 
differences were not statistically significant.  In contrast, over the next 10 minutes, the 
change in HR from peak values was significantly blunted for the CHT+/- animals.  
Finally, over the final 40 min of recording, genotype differences in HR recovery were 
lost.  
 
CHT Hemizygosity Results in Impaired Baroreceptor Sensitivity. 
 
The increase in resting HR and the inability to return from an activity-dependent 
HR after exercise suggested a decrease in the vagal tone in regulating the chronotropic  
A* ******
B
* * * * *
Time (min) post-exercise
Fig. 16. Reduced HR recovery after moderate exercise in CHT+/- mice.
(A) Averaged HR recordings in CHT+/+ and CHT+/- mice undergoing
moderate exercise (13m/min) for 5 min. Baseline HR recorded in home
cage for 10 min; 5-min exercise run; then 40-min post-exercise HR
recovery monitoring (B) Change in exercise HR from maximal HR.
obtained during exercise at 2-minute intervals. CHT+/+, n=9; CHT+/-,
n=8. Mean (±SEM) values are indicated (*P<0.05; one-tailed, paired,
Student’s t-test).
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control of the heart.  To further elucidate the vagal contribution to HR response in 
CHT+/- mice, we measured baroreceptor-mediated changes in HR response following 
intravenous administration of phenylephrine (PE) in anesthetized CHT+/+ and +/- mice.  
CHT+/+ and +/- mice exhibited similar anesthetized baseline mean arterial pressure, 
however CHT+/- higher baseline HR compared to CHT+/+ mice.  While both genotypes 
exhibited similar increases in BP to PE challenge, CHT+/- mice demonstrated a marked 
reduction in bradycardic response (Figure 17A).  The ratio of HR change to BP change 
during exposure to pressor agents has been used as an index of baroreceptor sensitivity 
(Lin et al., 2007).  CHT+/- mice also demonstrated a significant reduction in the ratio of 
the mean change in HR to the maximal mean BP change in response to 20 µg/kg PE 
challenge (P<0.03; Figure 17B).  These results indicate that CHT+/- mice exhibit 
impaired vagal regulation of HR response to acute changes in blood pressure and reduced 
baroreceptor sensitivity. 
 
CHT+/- Show an Enhanced Bradycardic Response to VNS, but Inability to Sustain 
Bradycardia to Chronic Stimulation. 
 
To directly determine the impact of CHT heterzygosity on vagal regulation of 
HR, the effect of stimulation of vagal efferents on HR was determined using two separate 
vagal nerve stimulation protocols.  In protocol 1, we examined the frequency-dependent 
change in the RR interval (RRI) in anesthetized mice.  CHT+/- mice exhibited 
significantly higher baseline heart rates. Stimulation of the right vagus nerve significantly 
increased RR interval in a frequency-dependent manner in CHT+/- mice indicating a 
hypersensitivity of vagal regulation of HR (Figure 18A).  Given the importance of CHT  
AB
*
Fig. 17. Blunted baroreceptor sensitivity (BRS) in CHT+/- mice. (A)
Averaged HR (bpm) (solid line) and BP (mmHg) (dotted line) recording in
anesthetized CHT+/+ (red) and CHT+/- (blue) mice during intravenous
infusions of phenylephrine 20 μg/kg. CHT+/- mice show similar changes
in BP, however fail to exhibit compensatory changes in HR similar to
CHT+/+ i (B) E ti ti f BRS iti it i d (Δ HR/Δ MBP)m ce. s ma on o sens v y n ex
ratio. CHT+/+, n=8; CHT+/-, n=8. Mean (±SEM) values are indicated
(*P<0.03; one-tailed, paired, Student’s t-test).
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Fig. 18. CHT+/- mice show altered HR responses to acute and chronic
VNS. (A) Change in RR-interval during frequency-response VNS
stimulation (5 and 10 Hz) at 30 sec. intervals. CHT+/- show significant
increase in RR-interval (reduced HR) at both 5 and 10 Hz frequencies vs.
CHT+/+ mice (CHT+/+, n=9; CHT+/-, n=8 P<0.004). (B) Smoothed HR
(bpm) tracings during chronic VNS (40Hz) over 3 min. CHT+/- mice
exhibit hypersensitive bradycardic response initially, but lose this effect
idl C / i (C) i ( ) 0% b limore rap y vs. HT+ + m ce. T me sec to 5 ase ne HR
recovery is also shorter in CHT+/- mice vs CHT+/+ mice (P=0.01). (D)
Percent (%) HR recovery at 1.0 min time interval is greater in CHT+/- vs.
CHT+/+ mice (P<0.05). Mean (±SEM) values are indicated (one-tailed,
paired, Student’s t-test).
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in maintaining the presynaptic pool of available ACh, we hypothesized that CHT+/- 
would be unable to maintain the bradycardic response to chronic, continuous vagal nerve 
stimulation.  Therefore in protocol 2, during chronic vagal stimulation (5 min) at 40Hz, 
CHT+/- exhibited a more pronounced decrease in HR, however (Figure 18B), the 
average rate of return of the HR in response to VNS (measured as the TT50%) was 
significantly faster in CHT+/- mice compared to CHT+/+ (Figure 18C and D) indicating 
an inability of CHT+/- mice to sustain prolonged vagal stimulation of HR. 
 
CHT+/- Mice Show Impairments in Cardiac Function. 
 
Ultrasonic echocardiography allows non-invasive determination of both cardiac 
function and structure throughout the entire cardiac cycle.  Chronic tachycardia exhibited 
by β1-adrenergic overexpressing mice display a significant decrease in 
echocardiographic determinations of cardiac function by 35 weeks (Engelhardt et al., 
1999).  Whereas body weights of CHT+/- and CHT+/+ mice did not differ, CHT+/- mice 
exhibited significantly increased heart/body weight ratios  (P<0.05; Figure 19A).  To 
explore this further, we utilized 2D- and M-mode echocardiography to determine the 
impact of chronic tachycardia in both young (4-6 month old) and aged (10-12 month old) 
CHT+/- mice.   Both young and aged CHT+/- mice (Table 5) show significantly 
diminished loss of cardiac contractility as shown by a reduction in left ventricular 
function (fractional shortening, %FS) (P<0.01; Figure 19B).  Although CHT+/- mice 
exhibited reduced left ventricular function, cardiac output (CO) was slightly higher in 
young CHT+/- mice, but similar in older CHT+/+ mice.  It is possible that this difference 
in CO seen in the young mice was due to increased heart rate, however these studies were  
A
*
B
**
C **
Fig. 19. Histologic and echocardiographic detection of cardiac
hypertrophy and diminished cardiac contractility in CHT+/- mice. (A)
The ratio of heart weight (HW; g) vs. body weight (BW; g) x1000. Values
are means (±SEM); CHT+/+, n=7; CHT+/-, n=9. *P<0.05. (B) 2-D
guided, M-mode derived echocardiography shows CHT+/- mice with
reduced left ventricular fractional shortening (FS%) in both young (4-6
mo) and aged (10-12 mo) mice. Mean (±SEM) values are indicated
(*P<0.01; one-tailed, paired, t-test). (C) LVM (g) is slightly elevated in
young CHT+/- mice vs young CHT+/+ mice. Aged CHT+/- show
significantly elevated LVM compared to aged CHT+/+ mice. Mean
(±SEM) values are indicated (**P<0.03; one-tailed, paired, Student’s t-
test). Young CHT+/+, n=8; CHT+/-, n=8. Aged CHT+/+, n=9; CHT+/-,
n=8.
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conducted in trained, conscious mice exhibiting similar “stressed” heart rates between 
genotypes.  Left ventricular mass (LVM) a sign of heart failure was also determined in 
CHT+/- mice.  Young CHT+/- showed a trend toward elevated LVM compared to 
CHT+/+ mice, however this did not achieve statistical significance.  However, in older 
CHT+/- mice, LVM was significantly increased compared to CHT+/+ mice (P<0.03; 
Figure 19C).  These results are consistent with other transgenic models displaying 
tachycardia and increased afterload (Engelhardt et al., 1999). 
 
CHT+/- Mice Display Aged-Related Cardiac Histologic Changes Consistent with 
Progressive Heart Failure. 
 
A typical pathologic response to chronic adrenergic stimulation of the heart often 
results in cardiac muscle hypertrophy characterized by fibrosis (Weber et al., 1991).  
Using quantitative analysis of Masson’s Trichrome stained sections, revealed increased 
interstitial fibrosis in aged, but not young CHT+/- mice as compared to CHT+/+ 
littermates (P<0.004; Figure 20A-E).  Histologic examining of cardiac myocyte area 
using PAS-H revealed similar age-dependent increases in mean myocyte are in CHT+/- 
mice (P<0.01; Figure 21A-E).  These results indicate that the sustained resting 
tachycardia seen in aged CHT+/- mice is sufficient to produce overall histologic 
pathology consistent with fulminate heart failure.   
 
Chronic Exercise Leads to a Trend of Improved Cardiac Function in CHT+/- Mice. 
 
 Although CHT+/- mice showed reduced vagal regulation of cardiovascular 
function, as evidenced by chronic resting tachycardia, hypertension and 
A BCHT+/+ CHT+/-
Yo
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g
C DCHT+/+ CHT+/-
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d
*E
Fig. 20. Cardiac interstitial fibrosis alterations in CHT+/+ and
CHT+/ mice M ’ T i h t i d 5 ti f- . asson s r c rome s a ne -um sec ons o
paraffin-embedded left ventricular myocardium from young (2-3
mo) and aged (10-12 mo) CHT+/+ (A, C) and CHT+/- (B, D) mice.
Arrows indicate areas of fibrosis. (E) Morphometrical analysis of
myocyte fibrosis shows that aged CHT+/- mice exhibit significantly
higher left ventricular fibrosis compared to CHT+/+ mice.
Significance as determined by one-tailed unpaired Student’s t-test
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,
(genotype x same age group), *P<0.004, n=5/genotype. Values
represent ± S.E.M.
A BCHT+/+ CHT+/-
Yo
un
g
C CHT+/+ CHT+/-D
A
ge
d
E *
Fig 21 Comparison of cardiomyocyte alterations in CHT+/+. .
and CHT+/- mice. Periodic-Acid Schiff stained 5-um sections of
paraffin-embedded left ventricular myocardium from young (2-3
mo) and aged (10-12 mo) CHT+/+ (A, C) and CHT+/- (B, D) mice.
Arrows indicate areas of myocyte hypertrophy. (E) Morphometrical
analysis of mean cardiomyocyte area shows similar cardiomyocyte
area in young CHT+/+ and CHT+/- mice. However, aged CHT+/-
96
mice display significantly increased cardiomyocyte area versus
CHT+/+. Significance as determined by one-tailed, unpaired
Student’s t-test (genotype x same age group), *P<0.01,
n=5/genotype. Values represent ± S.E.M
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echocardiographic and histologic changes consistent with mild cardiac hypertrophy, they 
do not exhibit overt physical symptoms of heart failure.  Thus CHT hemizygosity may be 
sufficient to sustain adequate baseline ACh stores capable of delaying heart failure.  
Cardiac hypertrophy is a normal adaptive response to chronic exercise, however the 
hypertrophic response can be associated with cardiac disease and heart failure in the 
presence of reduced vagal tone or sympathetic hyperactivity (LaCroix et al., 2008; 
Medeiros et al., 2008).  Conversely, chronic moderate exercise has also been shown to 
improve autonomic balance in mice and to delay cardiac dysfunction (De Angelis et al., 
2004; Medeiros et al., 2008).  Therefore, we conducted chronic exercise studies to 
examine the impact of CHT hemizygosity on development of cardiac hypertrophy.  
Consistent with earlier findings, CHT+/- mice in both the control and exercise-swim 
group showed significantly reduced fractional shortening (%FS) compared to CHT+/+ 
mice in both control and exercise groups (CHT+/+ control, n=4, 50.38±0.8; CHT+/-, n=4, 
38.55±0.5; CHT+/+ exercise, n=4, 49.83±0.2; CHT+/- exercise, n=3, 41.73±1.3) (Figure 
22A).  Baseline HRs were not significantly different between groups or between 
genotypes.  Derived calculations for baseline cardiac output (CO) showed no significant 
differences between groups or genotypes at baseline, although there was a trend of the 
LV mass (LVM) to be increased in both groups of CHT+/- mice  (Figure 22B).  At the 
end of the 30-day chronic swim exercise cardiac function indices (FS%, CO and 
LVmass) in both CHT+/+ mice control and swim groups were unchanged from baseline 
(Figure 22A and B).  In the CHT+/- mice, both the control and swim groups surprisingly 
showed an improvement in FS% (Figure 22A), however CO and SV were similar to 
baseline values in the CHT+/- control group compared to the CHT+/- swim group.  These  
A*
*
*
B
Fig. 22. Chronic swim exercise and its impact on cardiac function in
CHT+/- mice. 2-D guided, M-mode derived echocardiography
measurement of (A) fractional shortening (%FS) and (B) left ventricular
mass (LVM) in 4-6 mo CHT+/+ and CHT+/- mice at baseline, during a 30-
day chronic swim and 1 month post-exercise. (*P<0.001 CHT+/+ vs
CHT+/- control and **P<0.01 CHT+/+ vs CHT+/- swim at baseline
(BSL); 2-way repeated measures ANOVA with Bonferroni post-test.
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results however were not significant when compared between groups at the end of the 
exercise period or change from baseline to exercise.  To determine if these changes 
observed in CHT+/- mice were exercise dependent, we repeated echocardiography in the 
same set of mice 1-month after the exercise training.  Quite surprisingly, FS% in both 
CHT+/- groups had reverted back to baseline values, while LV mass was slightly 
elevated compared to CHT+/+ mice.  While our experimental group size was small (N=3 
or 4/group), these results raise the possibility that the basal phenotypes observed in 
CHT+/- mice are not irreversible, however due to the short duration and small sample 
size further studies are needed to characterize the impact of exercise on cholinergic tone 
in CHT+/- mice. 
 
Discussion 
 
Cholinergically Mediated Regulation of Cardiovascular Function 
  To determine the impact of CHT hemizygosity on vagally mediated cholinergic 
regulation of HR, we examined HR recovery (HRR) and baroreceptor sensitivity (BRS) 
in CHT+/- mice.  The physiologic mechanisms of HRR and BRS are dependent upon the 
coordination of vagal-cholinergic and sympathetic efferents to the heart and vasculature.  
The overall importance of vagal regulation of HRR and BRS in cardiovascular disorders 
has been shown in several studies wither both HRR and BRS have been proven in human 
patients to be independent risk factors of mortality associated with cardiovascular disease 
(Cole et al., 2000; La Rovere, 2001). 
 100
To examine HRR, telemeterized CHT+/+ and CHT+/- mice were placed onto a 
treadmill and required to exercise at a constant speed (13m/min) for 5 min.  The speed 
and duration was chosen due to the motor deficits previously established in CHT+/- mice 
(Bazalakova et al., 2007), in addition to running difficulties due to the weight and 
placement of the implantable telemetry devices.  As previously seen, baseline resting HR 
was statistically elevated in CHT+/- mice compared to wild-type littermates.  During the 
5-min treadmill exercise run, both CHT+/+ and CHT+/- mice exhibited similar maximal 
HR increases (Figure 16A).  During the early phase of HRR immediately post-exercise, 
CHT+/- mice show an initial HRR similar to CHT+/+ mice, which plateaued 5-minutes 
into the HR recovery period, and stayed elevated 20 minutes into the recovery period 
(Figure 16A).  During the later phase of HRR (30-min post-exercise), CHT+/- mice 
slowly began to return back to baseline HR levels.  The initial HR recovery within the 
first 10 minutes post-exercise was similar between genotypes and may be reflective of a 
combination of similarities in withdrawal of sympathetic tone and increase in vagal tone, 
however studies using antagonists of both branches of the ANS would be required to full 
elucidate the contributions of the either SNS or PNS in early HRR.  Additionally, initial 
cardio-deceleration could be due to changes in venous return, since decreases in cardiac 
filling pressures have been shown to result in reduced HR (Chen et al., 1995).  From 12 
to 20 minutes post-exercise, CHT+/- exhibited a significant blunting of their HRR.  The 
HRR plateau seen in CHT+/- mice may be reflective of the lack of sustainable ACh due 
to insufficient intracellular CHT pools to mobilize to meet increased cholinergic 
demands.  Significant controversy exists as to the temporal contributions of the 
sympathetic and parasympathetic nervous system in regulation of HRR (Cole et al., 
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1999).  Although the majority of the data supports parasympathetic activation in the early 
phase of HR recovery after exercise in human and canine models, these data are lacking 
in rodent models.  One study conducted in rats demonstrated that parasympathetic 
contributions to HR recovery in hypertensive rats occurred within 20 minutes after 
exercise, similar to our findings in CHT+/- mice (Chen et al., 1995).  Additionally, 
attenuation of cardio-deceleration during HRR may be complicated by heightened 
sympathetic tone in our CHT+/- as our previous results demonstrated elevated cardiac 
tissue levels of catecholamines and blunted HR responses to the β-adrenergic receptor 
antagonist, metoprolol.   
Baroreceptors are stretch receptors located in the endothelium of the carotid sinus 
and aortic arch.  These receptors detect transient increases in blood pressure, which result 
in increased vagal transmission to the heart producing decreased HR and venodilation.  
Therefore, we hypothesized that CHT+/- mice may exhibit blunted BRS upon eliciting 
the vagal reflex due to transient increases in BP upon infusion with phenylephrine (PE).  
Both CHT+/+ and CHT+/- mice (CHT+/+, n=8; CHT+/-, n=8) exhibited similar 
anesthetized baseline mean arterial pressure (MAP), however CHT+/- mice had higher 
baseline HR compared to CHT+/+ mice.  Both CHT+/+ and CHT+/- mice showed similar 
increases in BP upon intravenous infusion of PE (CHT+/+, 22.50±2.2 mmHg; CHT+/-, 
19.43±1.9; p=0.359), however CHT+/- mice failed to elicit a robust decrease in HR 
compared to CHT+/+ mice (Figure 17). Comparison of the BRS index showed that 
CHT+/- mice demonstrated a significant reduction in the ratio of the mean change in HR 
to the maximal mean blood pressure change in response to PE challenge (Figure 17).  
These results indicate that CHT+/- mice exhibit impaired vagal regulation of HR 
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response to acute changes in blood pressure and reduced baroreceptor sensitivity.  Thus it 
was possible that these physiologic findings represented the inability of sensory afferents 
projecting to regulatory centers within the CNS to elicit a decrease in HR with changes in 
BP.  Similarly the inability of CHT+/- mice to return to resting HR as quickly as CHT+/+ 
mice may have been due to hyperactive sympathetic tone and not due to diminished vagal 
efferent regulation. 
Although HR recovery and BRS allowed us to examine inducible vagal tone, 
changes in HR due to either exercise cessation or pharmacologic manipulation could be 
influenced by feedback mechanisms and influences by sympathetic tone allowing only 
transient examination of vagal tone.  Therefore, we utilized vagal nerve stimulation 
(VNS) to directly examine the vagal efferent projection onto the heart and the impact of 
CHT hemizygosity on bradycardic responses to stimulation.   
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CHAPTER IV 
 
ASSOCIATION OF MUTATIONS IN THE HUMAN CHOLINE TRANSPORTER TO 
HUMAN DISEASE 
 
 
Introduction 
 
 Single nucleotide polymorphisms (SNPs) identified in various neurotransmitter 
transporters and having a functional impact on activity or trafficking, have been found to 
be associated with a number of human diseases (Garland et al., 2002; Hahn et al., 2008; 
Hahn and Blakely, 2002).  CHT-mediated HACU serves as the rate-limiting step for the 
synthesis of the neurotransmitter ACh, which functions to regulate a wide variety of 
physiologic and behavioral processes.  Thus, discoveries of genetic variants impacting 
the synthesis or release of ACh would be predicted to have a significant impact on both 
physiologic and behavior functions.  While evidence does not exist for CHT 
haploinsufficiency in human disease, Okuda, et al., identified a missense mutation 
occurring within an exonic region of the human CHT gene (Okuda et al., 2002) resulting 
in a hypomorphic transporter (<50% Vmax) with a minor allele frequency of 6%.  The 
presence of a hypomorphic variant in the human CHT may have significant impact on 
cholinergically-mediated physiologic and behavior functions.  Studies performed in 
CHT-/- and CHT+/- mice demonstrate the critical significance of CHT in survival 
(Ferguson et al., 2004), motor and behavioral functions (Bazalakova et al., 2007).   
An additional SNP has also been identified within the purported 3’UTR region of 
the human CHT gene (Neumann et al., 2005).  Although no functional data currently 
exists on this variant, the presence of the major allele has been associated with reduced 
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HRV (Neumann et al., 2005) and increased corticolimibic activation with physiologic 
arousal (Neumann et al., 2006) in healthy controls.  These studies indicate that the 
presence of the major allele SNP within the CHT 3’ region may attenuate cholinergic 
tone regulating HR variability and negative feedback control of the corticolimbic 
projections. 
Characterization of CHT+/- mice may provide invaluable information on the 
impact of CHT deficiency and its impact on behavioral or physiologic phenotypes, which 
may be extrapolated to human disease.  These early studies identifying SNPs within the 
human CHT in the context to our behavioral and cardiovascular findings in CHT+/- 
provide clues as to the role of CHT on cholinergic transmission regulating psychiatric or 
cardiovascular disorders.  
 
Human genetics of CHT 
 The human CHT is a member of the SLC5 (SLC5A7) family of mammalian Na+-
dependent transporters (Ferguson and Blakely, 2004).  The CHT gene is located on 
chromosome 2 and consists of 9 highly conserved exons spanning 25kb of genomic 
sequence (Figure 7) (Ferguson and Blakely, 2004).   Within CHT coding regions, only 
one SNP has been identified to reside within the exonic region of CHT, resulting in a 
non-synonymous coding variant +265 A/G (rs1013940), encoding an Ile to Val at amino 
acid position 89 exhibiting functional transport deficiency (Okuda et al., 2002).  This 
SNP has been shown to have a minor allele frequency of 6% in health controls (Okuda et 
al., 2002).  Another non-coding polymorphism, originally identified as a component of 
the CHT 3’ transcription stop site (+4037 G/T; rs333229), here designated the 3’SNP 
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(see Methods) has been associated with altered cholinergic tone, as measured by heart 
rate variability (HRV), and to altered corticolimbic reactivity to stress (Neumann et al., 
2006; Neumann et al., 2005).   Haplotype determination for both CHT Ile89Val and 3’ 
SNPs, shows that neither of these SNPs are in LD, with each SNP residing within its own 
haplotype block (Figure 9) (International HapMap Project, 2005).  
 
Cholinergic genes involved in neuropsychiatric disorders  
 Given the role of CHT function in maintaining the releasable pool of ACh, 
especially during high states of cholinergic tone, the possibility exists that 
polymorphisms having functional consequences on CHT may contribute to various 
psychiatric or cardiovascular diseases.   Alterations in cholinergic function have been 
shown to underlie various neuropsychiatric disorders such as schizophrenia, major 
depressive disorder, various anxiety disorders (ie. posttraumatic stress disorder, PTSD), 
Alzheimer’s disease (AD), attention deficit hyperactivity disorder (ADHD) and 
myasthenic syndromes (Coyle et al., 1983; Sarter and Parikh, 2005; Tandon, 1999; 
Vakalopoulos, 2007).  Disruptions in cholinergic transmission have been implicated in 
the cognitive impairments that are commonly seen in patients suffering from 
schizophrenia and several pharmacologic treatments which enhance cholinergic tone 
have been studied in various clinical trials to alleviate these impairments (Friedman, 
2004; Tzavara et al., 2004).  Additionally, nAChR agonists have been shown in animal 
models to ameliorate anxiogenic effects by increasing serotonin (5-HT) release from 
neurons within raphe nuclei (File et al., 2000).   
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 Genes regulating cholinergic neurotransmission have received considerable 
attention in disorders of cognition and memory such as ADHD and AD (Sarter and 
Parikh, 2005).   In AD, degeneration in basal forebrain cholinergic circuits contributes to 
cognitive impairments in the disorder.  Single nucleotide polymorphisms in several genes 
including nAChR and ChAT, mediating cholinergic neurotransmission have been found 
to be associated with AD (Cook et al., 2004; Cook et al., 2005).  Similarly, in ADHD, 
SNPs within subunits of nAChR (CHRNA4 and CHNRA7) have been found to be 
associated with the disease (Kent et al., 2001; Todd et al., 2003).   
 Given the role of CHT in the maintenance of ACh biosynthesis, we hypothesize 
that diseases that are modified by alterations in cholinergic tone may be influenced by 
deficits in CHT function.  Thus, these CHT variants may be enriched in patients suffering 
from disorders due to cholinergic disruptions.   
 
Cholinergic genes involved in cardiovascular disorders 
Acetylcholine is an important regulator of cardiac function, mediating processes 
such as heart rate and to a lesser degree, blood pressure.  Few studies have examined the 
role of SNPs in genes regulating cholinergic neurotransmission and the impact on 
cardiovascular health.  Most studies have focused on post-synaptic receptors (nicotinic or 
muscarinic) and their roles in facilitating cholinergic transmission and its regulation of 
the cardiovasculature.   
Regulation of blood pressure is critically important to the overall physiology of 
the heart and is tightly regulated predominantly by the sympathetic branch of the 
autonomic nervous system.  Nicotinic receptors mediate the post-synaptic transmission of 
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both the parasympathetic and sympathetic branches of the ANS.  Recently a SNP within 
the gamma subunit of the nicotinic receptor (CHRNG; rs2099489), encoding a 
synonymous SNP (Arg474 ->Arg474) was found to be associated with higher systolic BP in 
subjects from the Amish Family Diabetes Study (AFDS) (McArdle et al., 2008).   These 
results were also confirmed in a panel of subjects from the Framingham Heart Study 
(McArdle et al., 2008).  Though this SNP does not result in an amino acid substitution, it 
has been hypothesized to influence expression by altering pre-mRNA splicing, mRNA 
stability and efficiency of translation (Parmley et al., 2006).  Alternatively, it may not 
result in a functional consequence by be in linkage disequilibrium with a causative SNP, 
yet to be identified (Parmley et al., 2006). 
The negative chronotropic effects of ACh on the heart after exercise and its 
temporal regulation of HR recovery are not well known.  The effects of ACh in 
promoting the negative chronotropic effects of the heart are mediated by the muscarinic-2 
acetylcholine receptor (M2AChR) function to slow the heart rate down and diminish 
sympathetic tone to the heart via negative feedback mechanisms.  In a study examining 
the association of M2AChR SNPs with heart rate recovery, Hautala, et al., found an 
association of two M2AChR SNPs (rs324640 and rs8191992) were associated with HR 
and BP differences in the exercise group vs. controls (Hautala et al., 2006).  Subjects 
homozygous for the rs8191992 SNP exhibited higher LF-to-HF ratios indicative of 
reduced HRV post-exercise, a measurement of reduced vagal regulation of HR (Hautala 
et al., 2006).  Additionally, subjects with the rs324640 SNP exhibited higher resting 
diastolic BP (Hautala et al., 2006).  Though no functional data exists on these two SNPs 
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within M2AChRs, this study showed that genetic variants within the muscarinic receptor 
effect HRR and HRV and may predispose patients to increased risk of fatal arrhythmias.     
Our phenotypic characterization of the CHT+/- mice identified potential human 
phenotypes that may similarly be found in patients suffering from a number of disorders 
where loss of cholinergic tone has been identified as either causing or promoting 
pathology.  The behavioral and cardiovascular phenotypes observed in CHT+/- mice 
demonstrate the impact of a genetic loss of CHT and its role in regulating a number of 
cholinergically-mediated behaviors and physiology.  Thus patients carrying the 
hypomorphic CHT allele (Ile89Val) may suffer from a number of neuropsychiatric and 
cardiovascular disorders where loss of CHT function contributes to possible morbidity or 
mortality.  
In the experiments described below, I sought to identify the association and allelic 
transmission of the human hypomorphic CHT allele (Ile89Val) in subjects with primary 
Axis I psychiatric disorders, major depressive disorder and attention-deficit hyperactivity 
of which deficits in cholinergic function has been reported to affect neuropsychiatric 
physiology.  I also sought to examine a small group of subjects undergoing treadmill 
studies subjected to the QT prolonging drug, ibutilide to determine the role of the CHT 
Ile89Val hypomorph on resting and exercise HR. 
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Methods 
 
Allelic Discrimination genotyping assay (TaqMan®) 
An allelic discrimination assay was performed in the Vanderbilt Center for 
Human Genetics Research DNA Resources Core using TaqMan® SNP Genotyping Assay 
reagents (Applied Biosystems, Inc).  Four nanograms (ng) of whole genome amplified 
DNA were used as template in a reaction containing 900 nM of the following primer sets 
for CHT (Ile89Val, rs1013940); forward (5-TGTACCAGGTTATGGCCTAGCTT-3’) 
and reverse (5’-ACTGAGATTTGCACTTTCACTTACCT-3’) amplification primers, 200 
nM VIC® (5'-CAGGCACCAATTGGATA-3') and FAM® (5'-
AGGCACCAGTTGGATA-3') and for the CHT 3’SNP (rs333999); forward (5’-
GTGGACACACTTCTGGAGATTATACATTT-3’) and reverse (5’-
GTCCACGGGCCCTAATATTATATTCT-3’) and 200 nM VIC® (5’- 
CTCTTAATAATTCCCCCCCACACT-3’) and FAM® (5’- 
CTCTTAATAATTCACCCCACACT-3’) dye-labeled probes, and 1X TaqMan® 
Universal PCR Master Mix.  The 3’SNP has been previously described as the 3’UTR 
SNP (Neumann et al., 2006; Neumann et al., 2005), but our current genomic analysis 
place the variant 3’ of the predicted polyadenylation sites and could not be identified with 
deposited ESTs.  Thermal cycling (95°C for 10 min, followed by 50 cycles of 92°C for 
15 sec and 60°C for 1 min) and product detection was accomplished using the ABI 
7900HT Sequence Detection System (ABI). 
Following PCR and sample scanning, genotype calls were performed using the 
autocall feature of the SDS 2.2 software  (Applied Biosystems, Inc, Foster City, CA).  
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The SDS software utilizes an advanced multi-component algorithm to calculate distinct 
allele/marker signal contributions from the fluorescence measurements for each sample 
on a 384-well plate.  The SNP auto-caller was set at 95% confidence interval for each 
sample plate and genotypes cluster plot generated for each sample set (Figure  23A and 
B) . 
 
Selection for subjects with Major Depressive Disorder (MDD) 
 The clinical research protocol was approved by the Vanderbilt University 
Institutional Review Board.  Written informed consent was obtained from all research 
participants prior to any research procedures.  Subjects were recruited from the Adult 
Psychiatry Outpatient Clinic at the Vanderbilt University Medical Center.  Patients were 
overall physically healthy and were excluded if diagnosed with any of the following Axis 
I and II conditions:  schizophrenia, bipolar disorder, psychotic disorder; borderline, 
schizotypal or antisocial disorder.  Additionally, subjects were excluded if having a 
substance abuse diagnosis within 6 months prior to the assessment.   
 Patients (n=110) were evaluated using the Structured Clinical Interview for 
Diagnostic and Statistical Manual of Mental Disorder (DSM IV) and the Structured 
Clinical Interview for Axis II Personality Disorders (SCID).  Patient assessments of 
psychiatric conditions were evaluated using the 17-item Hamilton Rating Scale for 
Depression (HAM-D).  The mean age of the sample was 42.7 years (SD=10.7), 
consisting of 61% female and 39% male subjects.  Race was reported at 87% Caucasian, 
6.5% African-American, 4.6% Asian, 1% Hispanic and 1% other.  Major depressive 
disorder subtype was classified as 18% atypical, 35% melancholic and 47% no subtype.   
AB
Val/Val
Ile/Val
Ile/Ile
No calls and/or
Fig. 23. ABI TaqMan® methodology and representative data plot. (A)
   
controls
ABI TaqMan® assay involves the use of two TaqMan® minor groove
binder (MGB) probes labeled with the VIC® and FAM® dyes detecting
alleles 1 and 2 respectively. During PCR, each TaqMan® MGB probe
hybridizes to their respective SNP. DNA polymerase cleavage separates
the reporter dye from the quencher dye resulting in a fluorescence signal
thus indicating which alleles are present in the sample. (B) Representative
d l d b h ABI P i ® ll li di i i i d iata p ot pro uces y t e r sm a e c scr m nat on etect on
system. Individual genotypes are plotted based upon fluorescent
intensities. Black, controls; Red, homozygous major allele; Green,
heterozygous; Blue, homozygous minor allele.
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Sample selection of subjects with attention deficit hyperactivity disorder (ADHD) 
 Subjects for the ADHD association study were recruited from Emory University 
and the University of Arizona with the assistance of Irwin Waldman, Ph.D. and Ian 
Gizer, Ph.D., Department of Psychology, Emory University, Atlanta, GA.  Subjects 
(n=403) were recruited from 251 families at the two sites from clinics, which specialize 
in the assessment of childhood oppositional defiant disorders.   Parents of children 4-18 
were provided the Emory Diagnostic Rating Scale (EDRS), a symptom checklist 
developed to assess symptoms of major DSM-IV childhood psychiatric disorders.  
Parents were asked to rate their children’s symptoms as exhibited while off medication.  
Parents rated the symptom on a 0-4 scale, with 0 indicating that the symptom is “not 
characteristic” of the child, and 4 indicating that the symptom is “very much 
characteristic” of the child.  ADHD subtype was determined by obtaining the sum of the 
symptom checklist based upon parental responses.   
 
Sample selection of subjects enrolled in the Vanderbilt exercise study 
 Study design and study recruitment was performed by Prince Kannakeril, MD, 
MSCI with the Vanderbilt University Department of Medicine, Division of 
Cardiovascular Medicine.  Subjects (N=151) enrolled for this study were healthy human 
volunteers, aged 18-40.  Subjects performed two submaximal recumbent bicycle exercise 
tests, one drug-free and a second after 10 μg/kg intravenous ibutilide.  Continuous ECG 
monitoring is collected during both tests.  Analysis of beat-to-beat changes (heart rate 
variability) in RR interval and QT interval during exercise and recovery is assessed.  
Variability in baseline or drug-induced changes will be analyzed as a function of specific 
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polymorphism in CHT gene expected to affect the QT interval.  During the exercise 
periods, target HR was 120 bpm and continuous ECG monitoring and evaluation of RR 
interval and QT intervals were determined for HR at 90 bpm and 120 bpm.  Analysis of 
ECG measurements occurred at rest, during exercise (HR = 90 and 120; Ex90, Ex120) 
and recovery (HR = 90 and 120; Rec90, Rec120).  Subjects were genotyped for the 
hypomorphic CHT variant (Ile89Val; rs1013940) and the 3’SNP (rs333229). 
 
Statistical analyses used in the genetic association study of Major Depressive Disorder 
(Vanderbilt Panel) 
 The multivariate permutation test (MPT) was used to estimate statistical 
significance of association of genotype with clinical variables (Troendle, 1996).  This 
statistical approach was utilized because the conduction of multiple significance tests 
incrementally increases the family wise error (FWE), with Type 1 errors contributing to 
the failure of these studies.  Likewise, correction methods such as the Bonferroni method 
are too conservative and reduce power in these studies.  The MPT method does not 
assume independence and uses correlations among the outcome variables, resulting in 
increased statistical power.  The MPT method tests for statistical significance by 
comparison of the observed statistic to an empirical distribution of the test statistic, 
instead of the standard distribution typically used.   Further description of the utility of 
this statistical method can be found elsewhere (Hahn et al., 2008; Troendle, 1996) 
 The SAS statistical software package (SAS Institute, Inc., Cary, NC, USA) was 
used for all analyses with α=0.05.  PROC MULTITEST was used to perform stepwise 
MPTs of mean differences using a trend contrast with 20,000 permutations.   
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Statistical analyses used for genetic association study of ADHD (Emory Panel) 
 Family-based analysis of association and linkage using extensions of the 
Transmission Disequilibrium Test (TDT), and crosstab analysis using SPSS, were 
conducted by Irwin Waldman and Ian Gizer, Department of Psychology, Emory 
University, Atlanta, GA.  For the quality control group, crosstab analysis using SPSS v15 
(SPSS, Inc., Chicago, IL) were conducted for quality control analysis including measures 
of genotype reliability.  Call rates, Mendelian error rates and exact HWE tests and p-
values were estimated using PEDSTATS software (Wigginton et al., 2005). 
 We conducted family-based analyses of association and linkage using extensions 
of the TDT applicable to both categorical and continuous variables and tests of 
moderation (Dudbridge, 2003; Waldman et al., 1999).  Derived from the TDT, the 
family-based association test (FBAT) and pedigree-based association test (PBAT) 
software allow for the contribution of unaffected control subjects in the calculation of the 
FBAT statistic (Lange et al., 2003).   
 
Statistical analyses used for genetic association study of ADHD (Emory Panel) 
 Logistic regression analysis was used to test the null hypothesis of no association 
between our candidate CHT gene and RR-interval and QT-interval responses when the 
dependent variable has a bimodal distribution with a discrete cutoff point.  Assistance 
with newer statistical techniques for genetic analysis were provided by Marylyn Ritchie, 
PhD with the Vanderbilt Center for Human Genetics Research.  Significance tests will be 
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two-tailed, with a P-value of <0.05 considered significance.  Data was analyzed using 
SPSS for Windows version 11.5 (SPSS Inc., Chicago, IL). 
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Results and Discussion 
 
The CHT hypomorphic allele (Val) is associated with overall symptom severity in 
patients with MDD 
 The call rate in our sample set was 98% and confirmed using a previously 
reported RFLP PCR assay.  Allele frequency determination of the hypomorphic CHT 
Ile89Val in healthy controls has been reported to be 6% for the Val allele (Okuda et al., 
2002).  This minor allele frequency for the CHT Ile89Val variant was also confirmed in 
our Coriell control sample set (n=100), estimated at 6%.  Interestingly, in subjects 
suffering from MDD (n=122) the frequency for the Val allele was calculated to be 12% 
(Table 6).   For the 3’SNP, the estimated allele frequencies in subjects for MDD were 
similar to those reported in healthy controls (Table 6).  There were no significant Hardy-
Weinberg equilibrium (HWE) departures for the estimated genotypes.   
 Subphenotypic characteristics were also evaluated using MPT methods to 
determine association of the CHT Ile89Val alleles with symptom subtype and severity.  
Analysis of the MDD sample set with subphenotypic characteristics (n=110), showed a 
significant association of the Val allele with HAM-D-17 total score at intake or overall 
depression severity (P=0.04; OR=2.74 (1.05-7.18); Table 7) (Hahn et al., 2008).  There 
appeared to be a gene dose effect as HAMD-D-17 total intake scores for homozygous 
major allele (Ile) and heterozygous groups (Ile/Val) were lower compared to the 
homozygous minor group. 
 Disruptions in cholinergic signaling have been implicated in mood disorders 
(Janowsky et al., 1983).  Several genetic association studies and clinical trials of  
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antidepressant medications provide evidence for the role of cholinergic signaling in MDD 
(Furey and Drevets, 2006; Wang et al., 2004).  The findings of the association of the 
hypomorphic CHT (Val) allele with total HAM-D-17 score and overall depression 
severity supports the hypothesis that altered cholinergic tone regulates multiple traits 
within MDD. 
 
CHT Val allele is selectively overtransmitted with the Combined-subtype of ADHD 
 Subjects (Vandy sample, n=110; Emory sample, n=403) were genotyped for the 
hypomorphic CHT Ile89Val and the 3’SNP allele.  The call rate in our sample set was 
93% for the Ile89Val and 94% for the 3’SNP.  Allele frequency determination of the 
CHT Ile89Val and the 3’SNP in healthy controls has been reported to be 6% and 23% 
respectively (Neumann et al., 2005; Okuda et al., 2002).  The minor allele frequency for 
the both the CHT Ile89Val and 3’SNP variant was also confirmed in our Coriell control 
sample set (n=100), estimated at 6% and 24% respectively.  Interestingly, in subjects 
suffering from ADHD (n=110) the frequency for the Val allele was calculated to be 12% 
(Table 8).  There was no significant departure from HWE calculated in either sample set. 
 In our family-based trio analysis (n=403) of association of the ADHD diagnosis 
with the CHT Ile89Val and 3’SNP variants using FBAT, we found no evidence for 
association with either SNP across additive, dominant or recessive genetic models 
regardless of either analysis of affected or contrast with controls were determined.  
However, there was an association of the CHT Val variant with the Combined subtype of 
ADHD using the additive and dominant models (additive:  Z=2.19, one-tailed P=0.014, 
R2=0.09, OR=3.16; dominant:  Z=1.97, one-tailed P=0.024, R2=0.07, OR=2.79) 
Table 8. Allele frequencies of Ile89Val and 3’SNP CHT SNPs in ADHD.
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(Table 9).   Interestingly, the CHT Ile89Val SNP was also associated with the Inattentive 
subtype, however this association was with the major allele (Ile) and was strongest under 
the additive and recessive models (Table 9).   The 3’SNP variant was not found to be 
associated with either overall ADHD diagnosis, nor subtype (Table 10). 
 For the overall diagnosis of ADHD, as well as the Combined and Inattentive 
subtypes, we conducted an omnibus test of association for all haplotypes and followed 
this up by determination of specific haplotypes for the observed transmission in ADHD 
cases versus unaffected controls or transmissions in the diagnostic subtypes versus 
unaffected controls and all other subtypes.  All of the haplotype tests for either the 
ADHD diagnosis or the Inattentive subtype were non-significant (Table 11).  In contrast, 
the omnibus tests yielded a significant association with the Combined subtype under an 
additive model (Z=8.48, P=0.037) and a trend towards an association under a dominant 
model (Z=8.16, P=0.086) with the haplotype comprising both Ile89Val and 3’SNP minor 
alleles showing the strongest associations (additive model:  Z=2.65, P=0.008, R2=0.048, 
OR=2.25; dominant model:  Z=2.65, P=0.008, R2=0.069, OR=2.68) (Table 11). 
 In this study, the best fit model appeared to be the additive model vs. the 
dominant or recessive model, indicating that having 1 or 2 copies of the risk allele 
increased the likelihood of possessing the Combined subtype of ADHD in an additive 
fashion.  The preferential transmission of the CHT (Val) hypomorphic allele to the 
Combined subtype in the additive model may reflect the importance of cholinergic 
transmission in modulating both motor and attentional components of ADHD, such that 
the inheritance of the Val allele disrupts cholinergic tone to an extent to produce both 
attentional and motor deficits. Disruptions in cholinergic transmission have been 
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hypothesized to underlie deficits seen in animal models of both attention and 
hyperactivity (Gerber et al., 2001; Sarter and Parikh, 2005).   The finding of the CHT Ile 
major allele associated with the Inattentive subtype may reflect different genetic 
mechanisms modulating this subtype.  Although ACh plays a significant role in 
modulating attention, studies have also shown that the neurotransmitter NE has long been 
associated with modulating attention and there is strong evidence demonstrating that NE 
plays a role in the Inattentive subtype of ADHD (Beane and Marrocco, 2004; Biederman 
and Spencer, 1999). 
 
CHT Val allele is associated with impaired HR recovery after exercise 
 Genotyping was accomplished in 149 of 151 subjects revealing 2 distinct 
genotyping groups for the hypomorphic CHT allele, Ile89Val:  124 (Ile/Ile); and 25 
(Ile/Val).  There were no homozygous (Val/Val) for the CHT variant.  There was no 
difference between groups in resting HR or QTc (QT interval corrected for HR), either at 
baseline or after drug (Table 12).  Prior to ibutilide, there was no difference in QT Ex or 
QT Rec.  However, after ibutilide QT Ex was similar, but QT Rec was significantly 
shorter in the Ile/Val group.  In this study, the CHT Ile89Val polymorphism affected the 
QT interval during recovery from exercise when QT has been prolonged by drug.  Thus 
subjects carrying the hypomorphic CHT allele exhibit reduced cholinergic tone on 
ventricular repolarization in an exercise-dependent fashion.   
These findings have significant implications for sudden death during exercise and 
recovery, as well as QT-prolongation by drug.  For instance, the Autonomic Tone and  
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Reflexes After Myocardial Infarction trial (ATRAMI) established that autonomic tone 
after an MI was a strong predictor of mortality (La Rovere, 2001).  Another large study of 
5,234 subjects examining HR recovery after submaximal exercise demonstrated that 
abnormal HR recovery strongly predicted death due to ventricular arrhythmia (Cole et al., 
2000).  Kannankeril et al. showed that subjects with impaired ventricular function 
exhibited diminished parasympathetic tone compared to subjects with normal ventricular 
function, and that diminished parasympathetic tone failed to produce prolonged 
ventricular refractoriness shown to be anti-arrhythmic (Kannankeril and Goldberger, 
2002).  While subjects carrying the 89Val variant failed to show statistically elevated 
HRs compared to controls, these subjects failed to exhibit a QT-prolonging effect with 
ibutilide demonstrating a possible failure of the parasympathetic contribution to changes 
in action potential duration and increasing the risk of fatal arrhythmias by promoting raid 
repolarization of ventricular myocytes.  These data suggest that subjects carrying the 
hypomorphic 89Val allele may exhibit impaired parasympathetic tone or inability of 
parasympathetic tone to recover after exercise may result in an increased risk of sudden 
cardiac death.  
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CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
CHT Hemizygosity Produces Deficits in Cholinergically Mediated Physiology 
 
Previous work conducted by Ferguson, et al. in CHT-/- mice demonstrated the 
requirement of CHT for post-natal viability.  While CHT-/- mice were born at expected 
Mendelian ratios, CHT-/- pups appeared smaller, were largely immobile and exhibited 
hypoxia resulting in death within 1 hour (Ferguson et al., 2004).  Electrophysiologic 
studies conducted at sternomastoid NMJ show that while CHT-/- pups are born with 
normal stores of ACh, they are unable to sustain ACh availability during increased 
demands, resulting in motor and respiratory paralysis (Ferguson et al., 2004).  Similarly, 
immunofluorescence studies show that CHT-/- mice have disrupted NMJ formation with 
more diffuse nAChRs patterning compared to WT mice (Ferguson et al., 2004).  The 
post-natal lethality exhibited in CHT-/- mice limited further physiologic studies on the 
role of CHT loss on neuromuscular and autonomic regulation.  Although limited, studied 
conducted in CHT-/- mice demonstrated the requirement for CHT and its maintenance of 
ACh stores for viability. 
Conversely, the generation of CHT+/- mice provided a viable murine model for 
expanded physiologic studies.  Early studies conducted in CHT+/- mice show reduced 
CHT expression, but normal levels of [3H]choline uptake in whole brain extracts.  The 
findings of normal choline uptake in the presence of reduced CHT expression may reflect 
the increased shift of the vesicular pool of CHT to the plasma membrane to compensate 
for the reduced expression.  Subsequent studies however have shown that CHT+/- mice 
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show reduced choline uptake in synaptosomal preparations of the striatum and 
hippocampus, areas with significant cholinergic innervation (David Lund, unpublished 
observations).   
CHT+/- mice are born at normal Mendelian rates and appear and develop normal 
when compared to WT littermates.  Though CHT+/- mice do not display an overt 
phenotype, solicitation of behaviors or pharmacologic challenges dependent upon 
sustainable cholinergic tone result in phenotypic differences compared to CHT+/+ mice.  
For instance, CHT+/- mice show an increased sensitivity to the lethal effects of HC-3 
when compared to CHT+/+ mice demonstrated a reduced reserve capacity of CHT stores 
(Ferguson et al., 2004).  CHT+/- mice also display normal spontaneous behavioral 
characteristics, failing to show differences in sensory-motor, motor coordination, overall 
locomotor activity, anxiety and spatial learning and memory tests when compared to 
CHT+/+ mice (Bazalakova et al., 2007).  However, when CHT+/- mice are placed on a 
treadmill, they were incapable of sustaining exercise endurance or intensity compared to 
CHT+/+ mice.  Given that motor function requires continuous cholinergic transmission at 
the NMJ, deficits in the maintenance of ACh stores due to loss of CHT reserve is 
predicted to produce deficits in motor function.  Conversely, studies conducted in CHT 
mice displaying overexpression of CHT driven by a neuromuscular junction specific 
promoter (Hb9:CHT) show enhanced treadmill performance (David Lund, unpublished 
observations) demonstrating the role of CHT in maintaining cholinergic tone at the NMJ. 
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CHT Heterozygous Mice as Genetic Susceptibility Models of Cardiovascular 
Disease 
 
 
Several murine models of cholinergic dysfunction have identified changes in CHT 
function and expression demonstrating compensatory mechanisms for CHT regulation in 
the maintenance of ACh transmission (Bazalakova and Blakely, 2006).  The observations 
of reduced sensitivity to pharmacologic challenge to HC-3 and diminished exercise 
capacity in CHT+/- mice (Bazalakova et al., 2007) led us to search for additional 
physiologic functions dependent upon sustained cholinergic activation.   Homeostatic 
regulation of HR and BP is mediated by the sympathetic and parasympathetic branches of 
the autonomic nervous system.  Parasympathetic regulation of the heart produces direct 
negative inotropic and chronotropic effects, while parasympathetic-mediated regulation 
of endothelial nitric oxide, produce vasodilatory effects, both mediated by sustainable 
ACh transmission.  Therefore, we hypothesized that CHT+/- mice would exhibit deficits 
in parasympathetic (vagal) regulation of HR and BP. 
 
CHT+/- Mice Exhibit Tachycardia and Hypertension 
 CHT+/- mice develop normally into adulthood exhibiting similar weight, motor 
and behavioral characteristics to CHT+/+ mice under normal conditions.  The lack of 
distinguishable phenotypes may reflect compensatory changes in CHT regulation as 
demonstrated by biochemical studies in the CNS (Bazalakova et al., 2007).  Similar 
compensatory changes in CHT function and regulation have been seen in other models of 
cholinergic dysfunction (Bazalakova and Blakely, 2006; Xie et al., 2000), providing 
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evidence of the dynamic regulation of cholinergic synthesis pathways in maintaining 
ACh transmission. 
    To determine the role of CHT hemizygosity on vagal regulation of HR and BP, 
we utilized implantable cardiac telemetric devices in conscious mice.  Our initial findings 
demonstrated that CHT+/- mice exhibited higher resting HRs and BP compared to 
CHT+/+ mice.  Since both parasympathetic and sympathetic branches utilize ACh as 
their neurotransmitter at the preganglionic junction, we hypothesized that since the 
parasympathetic branch relied on ACh at both pre and post-ganglionic junctions that 
autonomic deficits would reflect deficits in PNS tone to the heart.  Preliminary data in 
older CHT mice (1.5 years) showed that CHT+/- mice displayed hypersensitivity to 
ganglionic blockade (Mihaela Bazalakova; unpublished data) by demonstrating 
significant reductions in HR.  These results demonstrate that CHT+/- mice exhibit 
nAChR hypersensitivity with the sympathetic branch as the predominant regulator of HR 
in CHT+/- mice.  Similar effects have been seen in patients suffering from multiple 
system atrophy (MSA) whereby lesions within the rostral ventrolateral medulla affect 
autonomic regulation of HR and BP (Diedrich et al., 2002; Diedrich et al., 2003; Parikh 
et al., 2002).  Patients suffering from MSA have been shown to have greater residual 
sympathetic tone as evidenced by dramatic changes in BP and HRV with the addition of 
the ganglionic blocker trimethephan (Diedrich et al., 2003).   
 The role of cholinergic neurotransmission in BP regulation is less clear.  The 
modulation of BP control via cholinergic mechanisms seems to involve both central and 
peripheral mechanisms.  For instance, direct microinjection of ACh into the NTS 
involves the activation of NO from nNOS and facilitates sympathoinhibitory responses 
 132
resulting in reduction of HR and BP (da Silva et al., 2008).   Within the periphery, 
cholingeric blockade via atropine markedly potentiated the NOS inhibitor L-NMMA 
increases in MAP (Lepori et al., 2001).  These studies point to the possibility of both 
central and peripheral effects of cholinergic regulation of BP mediated by the effects of 
NO and activation of the cGMP pathways resulting in vasodilation.  Thus, in addition to 
tachycardia, the hypertensive phenotype observed in CHT+/- mice may be the result of 
loss of cholinergic tone mediated via NO pathways.   Though CHT+/- mice displayed 
reduced sensitivity to PE, there were no observable differences between genotypes when 
examining the impact of the nitric oxide donor, SNP during the BRS experiments. 
Given the findings of elevated resting HR and BP in the CHT+/- mice, it would 
be interesting to examine further the specific contributions of either the sympathetic and 
parasympathetic branches to modulating these cardiovascular parameters.  Determination 
of baseline and pharmacologic manipulation of heart rate variability would provide useful 
information on the relative contributions of both branches of the ANS on HR and BP.  
Unlike in humans, where the HF component represents the PNS contribution to HRV, 
PNS modulation of HRV is seen within the LF component in mice (Gehrmann et al., 
2000).  Decreased HRV as reflected by reductions in the LF and HF/LF ratio has been 
seen in β1-adrenergic receptor overexpressing mice and mice with reduced functional 
Gαi-IKACh coupling (Gehrmann et al., 2002; Mansier et al., 1996).  Therefore, I would 
predict that the CHT+/- mice would have reduced HRV as reflected by reductions in the 
LF component, indicative of reduced parasympathetic tone. 
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Alterations in Cholinergic Synthesis and Transmission Pathways Underlie CHT+/- 
Cardiovascular Dysfunction 
 Elevations in HR and BP observed in CHT+/- mice may be explained by 
dysregulation of parasympathetic tone to the heart at either the presynaptic or 
postsynaptic level.  Indeed, we observed that CHT+/- mice had reduced atrial HACU and 
CHT protein expression compared to CHT+/+ mice.  Similarly we observed reductions in 
cardiac tissue levels of ACh and choline.  These results lead to the hypothesis that 
reduced presynaptic synthesis of ACh results in altered parasympathetic tone to the heart 
resulting in tachycardia.  At the postsynaptic level, we observed increased M2AChR 
protein expression in CHT+/- mice compared to CHT+/+ mice.  This may reflect a 
compensatory mechanism by which to maintain chronotropic and inotropic homeostasis 
of the heart, as these effects are similarly seen in patients and animal models of MI and 
HF (Brodde and Leineweber, 2004; Dunlap et al., 2003).   
 Though we observed a decrease atrial HACU and tissue ACh levels, the impact of 
partial loss of CHT on vagal release of ACh needs to be explored further in vivo.  
Dialysate ACh has been measured during vagal nerve stimulation in the cat as a measure 
of postsynaptic ganglionic vagal regulation of the myocardium (Akiyama and Yamazaki, 
2001; Kawada et al., 2001).  Similar studies conducted in CHT+/- mice would provide 
information on the impact of genetic loss of CHT on ACh release and disposition at the 
heart.  Additionally, though CHT+/- mice exhibited similar M2AChR protein expression 
levels compared to wildtypes, in light of hypersensitivity of bradycardic response to 
VNS, these results should be examined functionally via carbachol induced GTPγS 
stimulation of atrial preparations to reveal detailed information on the receptor-coupling 
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modulation of HR regulation.  As previously mentioned, changes in cardiac postsynaptic 
M2AChR expression and coupling have been identified in patients with HF (Dunlap et 
al., 2003), a condition often associated with tachycardia and elevated sympathetic tone 
and may represent a protective compensatory mechanism as deficits in M2AChRs have 
been shown to increase ventricular function to adrenergic stress (Kawada et al., 2001; 
LaCroix et al., 2008).   
 In vivo dialysis experiments examining ACh release during vagal nerve 
stimulation would provide detailed information on the disposition of ACh in CHT+/- and 
may explain why CHT+/- mice have elevated resting HRs whereas vagal tone is expected 
to increase.  Additionally, examination of M2AChR coupling in CHT+/- mice would 
reveal whether CHT+/- mice show increased coupling in addition to M2AChR protein 
expression.   Increased M2AChR protein expression and coupling would be expected to 
result in a increased parasympathetic effect at the heart, producing bradycardia rather 
than tachycardia, however it would be expected that CHT+/- mice though eliciting a 
hyperresponsive effect during acute ACh release, would not be able to sustain this 
bradycardic effect given to their inability to sustain ACh synthesis with increased 
cholinergic demand. 
The findings of differential effects of vagal nerve stimulation on HR regulation in 
CHT+/- mice provided evidence for the acute vs. chronic vagal activation on HR.  During 
our acute VNS trials, CHT+/- mice exhibited an increased bradycardic effect compared to 
CHT+/+ mice, leading to the possibility of increased postsynaptic hypersensitivity of 
M2AChRs.  However, during our chronic VNS experiments, CHT+/- mice that exhibit a 
significant bradycardic effect were unable to sustain this bradycardic effect and showed 
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greater HR recovery of their baseline HRs compared to CHT+/+ mice.  These finding 
point to possible compensatory alterations at the postsynaptic level in the heart due to 
changes in presynaptic CHT expression and function.  Similar findings have been 
observed within the CNS of CHT+/- mice (Bazalakova et al., 2007).  It will be of interest 
to conduct in vivo dialysis and experiments to determine the impact of CHT heterzygosity 
on ACh release during acute and chronic vagal nerve stimulation.  Similarly, direct 
GTPγS stimulation experiments will determine changes in receptor-effector coupling 
mediating these postsynaptic effects on HR regulation. 
In our in vivo studies examining baroreceptor reflex and heart rate recovery post-
exercise challenge, CHT+/- mice demonstrated deficits blunted BRS sensitivity and 
reduced HRR after-exercise, both functional tests which have been shown to be 
independent predictors of increased mortality (Cole et al., 2000; La Rovere et al., 2008).  
Functionally, these studies are an index of parasympathetic tone of HR and BP regulation 
and in CHT+/- mice demonstrate deficits in parasympathetic tone producing increased 
resting HR and elevated BP.  These studies, though complimenting the VNS and 
telemetric studies, do not rule out the possibility of elevated sympathetic tone 
contributing to the blunted BRS and HRR.  We demonstrated that CHT+/- mice have 
both increased urinary NE levels and blunted HR response to the beta-adrenergic 
antagonist, metoprolol.  These findings point to elevated sympathetic tone in CHT+/- 
mice, but whether this is due to a loss of direct actions of parasympathetic tone to the 
heart or loss of vagal feedback on sympathetic tone at the level of the brainstem remains 
to be elucidated.  It would be interesting to see if CHT+/- mice display altered sensitivity 
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to the α2-adrenergic agonist clonidine, which exerts its BP reducing properties by 
centrally acting mechanisms.   
 CHT plays a critical role in the maintenance of ACh biosynthesis and cholinergic 
transmission.  In vivo physiologic studies in CHT+/- mice reveal cardiovascular 
phenotypes of resting tachycardia and elevated BP, both of which can result in adverse 
cardiovascular events.  Though our studies point to reduced parasympathetic tone to the 
heart, genetic loss of CHT does not appear to produce overt heart failure, but may 
contribute to cardiovascular and neuropsychiatric pathology as a disease susceptibility 
gene (Figure 24).  Our echocardiographic and histologic findings of reduced fractional 
shortening and cardiomyocyte hypertrophy in older CHT+/- mice are consistent with 
those phenotypic findings in animal models and human patients with HF (Medeiros et al., 
2008; Olshansky et al., 2008), and point to the role of CHT as a potential risk factor or 
disease modifying gene in age-dependent cardiovascular disorders.  These findings of 
elevated HR, blunted BRS and reduced HRR in CHT+/- mice provide insight into the 
modulation of cardiovascular phenotypes in patients with cardiovascular disorders.  
However to fully explore the reserve capacity of CHT on the autonomic regulation of 
cardiovascular physiology, further reduction of CHT function using either tissue specific 
targeted deletion of CHT in vagal efferents or virally mediated strategies to produce 
additional suppression of CHT activity resulting in increased sympathetically-mediated 
pathology.  The finding of a hypomorphic allele in the human CHT gene (Ile89Val) 
(Okuda et al., 2002) lends us the opportunity to examine the role of this variant as a 
disease risk allele in patients with cardiovascular disease. 
  
Fig. 24. Genetic loss of CHT as a disease modifying susceptibility gene.
CHT mediated HACU contributes to the homeostatic functioning of
parasympathetic (vagal) tone by maintenance of releasable pools of ACh.
Genetic loss of CHT, reduces parasympathetic activity and increases the
susceptibility to various cardiac, metabolic and neurologic insults by
preventing the ability of the PNS to modulate these insults. Diminished
vagal tone in addition to these physiologic and neurologic insults adds to
i d li d i f dincrease morta ty an progress on o sease.
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Though our human genotyping studies in cardiovascular populations were limited 
to predominantly healthy subjects, subjects suffering from MDD and ADHD show 
considerable co-morbidity with cardiovascular disorders such as HTN and MI.  This 
suggests that patients with reduced functioning CHT may exhibit both brain and 
cardiovascular phenotypes.  Our findings that the 89Val allele is preferentially 
overtransmitted to patients with the combined subtype (inattentive and hyperactive) of 
ADHD are consistent with cholinergic function in regulating both behavior and motor 
functions.  Given the treatment refractoriness and aggressive treatment of this subtype 
with psychostimulants, these patients may require increased monitoring of their 
cardiovascular health given these associations.  
 In a study of healthy subjects undergoing moderate exercise testing, subjects with 
the 89Val allele had decreased QTc prolongation in the presence of ibutilide.  These 
findings are intriguing in that calculation of QTc using Bazett’s formula corrects for 
changes in QT interval due to HR, however the 89Val subjects fail to have a QT-
prolonging effect with ibutilide after heart stress indicating the possibility of failure of the 
parasympathetic tone in increasing action potential duration (APD) in ventricular 
myocytes, potentially increasing the risk of fatal arrhythmias by promoting rapid 
repolarization of ventricular tissue post-exercise recovery (Magnano et al., 2002).   
 Additional genotyping studies in human subjects demonstrated an increased 
association of the 89Val allele with overall symptom severity in patients with major 
depressive disorder (Hahn et al., 2008).  Although the cholinergic system receives less 
attention than the adrenergic system in mood, cholinergic mechanisms have been 
implicated in mood and mood disorders (Janowsky et al., 1983).  Similarly, patients with 
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major depressive disorder have also been shown to exhibit reduced HRV (Brown et al., 
2009).  While our phenotypic data in our MDD subject group was limited to psychiatric 
phenotypes, it is possible that subjects with the 89Val variant exhibit reduced HRV.  The 
reduction in vagal tone to the heart and subsequent reductions in HRV and HRR in 
patients with MDD, may explain why these patients are at increased risk for 
cardiovascular mortality (Hughes et al., 2008). 
 Further genetic studies in both healthy subjects and subjects with cardiovascular 
and neuropsychiatric disorders will reveal novel insights into the role of CHT as a disease 
modifying gene in a variety of cardiovascular and neuropsychiatric disorders.  Interest in 
CHT as a disease-modifying gene affecting cognitive-related disorders is evident by 
several patents recently filed with the US Patent office for SNPs within the human CHT 
for use as genetic markers in identifying late-onset AD.  Studies in rodent models 
showing changes in CHT activity and trafficking during sustained-attention tasks 
(Apparsundaram et al., 2005; Arnold et al., 2002), and the most recent finding of the 
CHT hypomorphic allele associated with combined subtype of ADHD implicate the role 
of CHT in sustaining cholinergic tone in a number of cognitive and movement disorders.  
Additionally the investigating the impact of CHT on HRV, BRS and HRR may serve as 
useful in providing a potential biomarker of cholinergic tone affecting both psychiatric 
and cardiovascular health.  Thoroughly designed genetic studies involving the CHT 
Ile89Val allele in addition to other risk variants associated with cardiovascular and 
neuropsychiatric disorders, would provide great insights into potential gene-gene (GxG) 
and gene-environment (GxE) interactions as seen with the 5HTTLPR polymorphism in 
depression and posttraumatic stress disorder (PTSD) (Caspi et al., 2003; Xie et al., 2009).    
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 In summary, the biochemical, physiologic and genetic association studies 
proposed above will provide further insight into the impact of CHT haploinsufficiency in 
sustaining ACh synthesis and cholinergic function in cardiovascular and neuropsychiatric 
disorders, and as a risk allele in modulating prognostic outcomes of these disorders. 
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